



Membrane Fatty Acid Transporters as Regulators of
Lipid Metabolism: Implications for Metabolic Disease
Citation for published version (APA):
Glatz, J. F. C., Luiken, J. J. F. P., & Bonen, A. (2010). Membrane Fatty Acid Transporters as Regulators
of Lipid Metabolism: Implications for Metabolic Disease. Physiological Reviews, 90(1), 367-417.
https://doi.org/10.1152/physrev.00003.2009





Publisher's PDF, also known as Version of record
Document license:
Taverne
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.




Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 03 Nov. 2021
Membrane Fatty Acid Transporters as Regulators of Lipid
Metabolism: Implications for Metabolic Disease
JAN F. C. GLATZ, JOOST J. F. P. LUIKEN, AND AREND BONEN
Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands;
and Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Canada
I. Introduction 368
II. Mechanism of Transmembrane Transport of Fatty Acids 368
A. Membrane fatty acid transport mediated by lipids or proteins? 369
B. Evidence for the involvement of membrane proteins 370
III. Membrane-Associated Fatty Acid Transporters 373
A. Plasma membrane fatty acid binding protein 373
B. Fatty acid translocase/CD36 374
C. Fatty acid transport proteins 375
D. Caveolins 377
E. Overall conclusions on fatty acid transporters 378
IV. Functioning and Subcellular Localization of Fatty Acid Transporters 378
A. Subcellular translocation of fatty acid transporters 378
B. Posttranslational modification of fatty acid transporters 381
C. Functioning of fatty acid transporters in mitochondrial fatty acid utilization 382
D. Coordinated functioning of fatty acid transporters 383
E. Do fatty acid transporters channel fatty acids to a particular metabolic fate? 384
V. Signaling and Trafficking Events Regulating Membrane Transporter Translocation 385
A. Signaling pathways 385
B. Trafficking pathways 389
VI. Chronic Physiological Regulation of Fatty Acid Transporters 391
A. Regulation of fatty acid transporter expression 391
B. Effects of development, ageing, and gender 392
C. Effects of fasting, hormones, and exercise training 393
VII. Alterations in Fatty Acid Transporters in Disease 394
A. Cardiac hypoxic disease and heart failure 394
B. Insulin resistance and type 2 diabetes 396
C. Type 1 diabetes 402
VIII. Conclusions and Perspectives 403
A. Integration of regulatory steps 403
B. Fatty acid transporters as potential therapeutic targets 404
Glatz JFC, Luiken JJFP, Bonen A. Membrane Fatty Acid Transporters as Regulators of Lipid Metabolism:
Implications for Metabolic Disease. Physiol Rev 90: 367–417, 2010; doi:10.1152/physrev.00003.2009.—Long-chain fatty
acids and lipids serve a wide variety of functions in mammalian homeostasis, particularly in the formation and dynamic
properties of biological membranes and as fuels for energy production in tissues such as heart and skeletal muscle. On
the other hand, long-chain fatty acid metabolites may exert toxic effects on cellular functions and cause cell injury.
Therefore, fatty acid uptake into the cell and intracellular handling need to be carefully controlled. In the last few years,
our knowledge of the regulation of cellular fatty acid uptake has dramatically increased. Notably, fatty acid uptake was
found to occur by a mechanism that resembles that of cellular glucose uptake. Thus, following an acute stimulus,
particularly insulin or muscle contraction, specific fatty acid transporters translocate from intracellular stores to the
plasma membrane to facilitate fatty acid uptake, just as these same stimuli recruit glucose transporters to increase
glucose uptake. This regulatory mechanism is important to clear lipids from the circulation postprandially and to rapidly
facilitate substrate provision when the metabolic demands of heart and muscle are increased by contractile activity.
Studies in both humans and animal models have implicated fatty acid transporters in the pathogenesis of diseases such
as the progression of obesity to insulin resistance and type 2 diabetes. As a result, membrane fatty acid transporters are
now being regarded as a promising therapeutic target to redirect lipid fluxes in the body in an organ-specific fashion.
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I. INTRODUCTION
The importance of long-chain fatty acids and lipids
for mammalian homeostasis is well recognized. Fatty ac-
ids (for convenience this term is used to designate “long-
chain fatty acids,” unless otherwise indicated) are primar-
ily known as constituents of “fat,” which represents a
crucial and efficient energy store due to the high energy
content per unit weight. Apart from their fundamental
role as a fuel for energy production, fatty acids are incor-
porated into phospholipids forming the core of biological
membranes and serve in selected signal transduction
pathways to alter gene expression. However, largely due
to their hydrophobic properties, fatty acids also exert
harmful effects and may cause (acute) cellular injury (96,
235, 468). Taken together, these divergent characteristics
of fatty acids require that their transport among and into
tissues occurs through specific mechanisms that allow
their rapid and controlled distribution without the possi-
ble detrimental effects associated with their detergent-
like properties.
Dietary fats typically comprise 30–40% of energy
intake and consist mostly of long-chain fatty acids ester-
ified in triacylglycerols. Lingual and pancreatic lipases
will hydrolyze these triacylglycerols into monoacylglyc-
erol and fatty acids which then are taken up by jejunal and ileal
enterocytes, reesterified into triacylglycerols, and incor-
porated with other lipids, lipid-soluble vitamins, and apo-
lipoproteins into chylomicrons for subsequent secretion
into the circulation. Similarly, the liver secretes very-low-
density lipoproteins produced from fatty acids synthe-
sized de novo or taken up from blood plasma and subse-
quently esterified into triacylglycerols and apolipopro-
teins. Both chylomicrons, carrying exogenous lipids, and
very-low-density lipoproteins, carrying endogenous lipids,
undergo hydrolysis of their triacylglycerols by lipoprotein
lipase located at the surface of the capillaries, so as to
deliver the fatty acids into peripheral tissues. Fatty acids
stored in adipocytes are hydrolyzed by hormone-sensitive
lipase (HSL) and adipose tissue triacylglycerol lipase
(ATGL), and distributed to other tissues bound to albumin
via the circulation. Taken together, a complex system
operates to distribute fatty acids among various tissues.
The uptake of fatty acids by parenchymal cells, es-
pecially their translocation across the cell membrane, has
long been considered to occur by simple (passive) diffu-
sion, with the rate of uptake being determined primarily
by the rate of fatty acid delivery (blood flow  extracel-
lular concentration) and the rate of intracellular fatty acid
metabolism. However, from a physiological perspective, it
would be highly desirable to regulate the entry of fatty
acids into the cell to tune their uptake to the metabolic
needs and avoid possible harmful effects of excess fatty
acid accumulation. Specifically, the objective of such con-
trol would be 1) to ensure fatty acid uptake when its
extracellular concentration is relatively low, 2) to limit
uptake when the extracellular fatty acid concentration is
relatively high, 3) potentially select for specific fatty acid
types, and 4) allow rapid adjustments in fatty acid provi-
sion at the local tissue level to meet rapid fluctuations in
metabolic demands, especially in heart and skeletal mus-
cle.
In the past few decades it has become clear that
various membrane-associated fatty acid-binding proteins
(termed “fatty acid transporters,” for convenience) facil-
itate the cellular entry of fatty acids, which are then
accepted by cytoplasmic fatty acid binding proteins
(FABPc). Furthermore, it has been found that acute
changes in fatty acid uptake in response to mechanical
(e.g., muscle contraction) and hormonal stimuli (insulin)
are regulated by specific membrane proteins, in a fashion
similar to the regulation of glucose uptake by glucose
transporters. Finally, studies in both humans and animal
models have implicated the membrane fatty acid trans-
porters in various metabolic aberrations and pathologies.
Thus a selective expression and/or regulation of specific
(sets of) membrane-associated and cytoplasmic fatty acid-
binding proteins could contribute to the control of the
fatty acid uptake and utilization processes, thereby en-
abling tissue-specific fatty acid uptake and utilization in-
dependent of fatty acid delivery. However, while FABPc
inside the cell functions as a sink for incoming fatty acids,
it displays merely a permissive action in cellular fatty acid
uptake in that only its full ablation reduces the rate of
cellular fatty acid uptake and utilization (32, 33, 280, 370;
for detailed reviews of FABPc, see Refs. 142, 188, 407). In
contrast, it appears that specific (sets of) plasma mem-
brane-associated proteins are central to regulating fatty
acid uptake and utilization.
In this review we discuss our current understanding
of the role of membrane fatty acid transporters in cellular
lipid metabolism, focusing on both the acute and chronic
regulation of cellular fatty acid uptake and on chronic
metabolic diseases, including myocardial disease, insulin
resistance, and types 1 and 2 diabetes. Data are presented
mostly for heart and skeletal muscle, as these tissues have
been studied most intensively, but the concepts to be
outlined generally may also apply to other tissues (see
sect. VIII). Other related and recent reviews have ad-
dressed changes in lipid and carbohydrate metabolism in
the failing heart (400), fatty acid metabolism in the type 2
diabetic heart (66), and skeletal muscle lipid metabolism
in exercise and insulin resistance (242).
II. MECHANISM OF TRANSMEMBRANE
TRANSPORT OF FATTY ACIDS
In recent years there has been considerable debate
on the mechanism by which fatty acids are taken up by
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cells, that is, how fatty acid transport occurs across the
plasma membrane, between the aqueous phases on either
side of this barrier. The dispute centers around the rate-
limiting kinetic step in this process, being either the ad-
sorption of fatty acids to, or insertion into, the outer
leaflet of the lipid bilayer, the subsequent transfer to the
inner leaflet (referred to as flip-flop), or the desorption
from the membrane into the aqueous phase (163), and
whether one or more membrane proteins could facilitate
either one or all of these steps or serve distinct functions
in the overall uptake process. Below we discuss specific
features and limitations of the methodologies and the
experimental models used. The reader is referred to early
(161, 163) and more recent (162, 233) reviews of the
controversies concerning the rate-limiting processes in-
volved in transferring fatty acids through the plasma
membrane.
A. Membrane Fatty Acid Transport Mediated
by Lipids or Proteins?
When considering the cellular uptake of fatty acids, the
physical transport can be regarded as seven kinetic steps:
1) dissociation of fatty acid from extracellular albumin into
the aqueous phase; 2) diffusion through the outer aqueous
phase; 3) insertion into the outer leaflet of the phospholipid
bilayer; 4) flip-flop from the outer to the inner leaflet, defined
as the complete movement of the fatty acid across the
bilayer with reorientation of the carboxyl head group from
the outer lipid-water interface to the inner lipid-water inter-
face; 5) dissociation from the inner leaflet; 6) diffusion
through the inner aqueous phase; and 7) binding to FABPc.
Thereafter, the fatty acid may be activated to its acyl-CoA
ester and undergo further metabolism.
The aqueous solubility of fatty acids, earlier esti-
mated to be in the micromolar range (395), is now recog-
nized to be extremely low, in the range 1–10 nM (465),
indicating that virtually all of the fatty acids will be
present in membranes or bound to proteins. The soluble
fatty acid binding proteins allow fatty acids to be miscible
in aqueous environments. Thus albumin in the circulation
and interstitium (348) and FABPc in the cytoplasm (141,
350) act as extracellular and intracellular buffers, respec-
tively, for fatty acids so that under normal physiological
conditions (total fatty acid concentration in the range
100–400 M) generally only 1 part in 105 is present in
the aqueous phase. In line with this, the average concen-
tration of (non-protein bound) fatty acids in human
plasma was reported to be 7.5  2.5 nM (349).
Different approaches and model systems have been
used to delineate the rate governing kinetic step in the
overall cellular fatty acid uptake process. Various groups
have studied fatty acid transport across the lipid bilayer of
artificial phospholipid vesicles by incubating these vesi-
cles with fatty acids, or albumin-fatty acid complexes, and
monitoring either the appearance of fatty acids in the
internal aqueous phase of the vesicle or the change in pH
inside the vesicle that occurs as a result of the transmem-
brane movement of fatty acids. The intravesicular fatty
acid concentration has been measured using ADIFAB, a
fluorescent probe composed of acrylodan-derivatized in-
testinal type FABPc that allows the accurate assessment
of very low concentrations (nM) of fatty acids in aqueous
solutions without disturbing their binding equilibrium
with proteins or membranes (351). ADIFAB has been
trapped into phospholipid vesicles or erythrocyte ghosts
during their formation and has also been microinjected
into adipocytes (234). Alternatively, a pH-sensitive fluoro-
phore such as pyranine or 2,7-bis(2-carboxyethyl)-5(6)-
carboxyfluorescein (BCECF), has been trapped inside
phospholipid vesicles, to monitor the H that dissociates
from the transported (un-ionized) fatty acid upon its ap-
pearance at the inner leaflet of the bilayer (see below) (84;
for review, see Ref. 59). In earlier studies transport has
also been measured with fluorescently labeled fatty acid
analogs (251, 408), but the addition of a large fluorescent
moiety is expected to dramatically alter the physicochem-
ical properties of fatty acids, and therefore alter transport
rates (233). Because of these considerations, these stud-
ies will not be discussed here.
Hamilton and co-workers have monitored the move-
ment of fatty acids across phospholipid membranes using
pH-sensitive probes. When presented either as albumin-
fatty acid complex, dissolved in organic solvent, or as the
K soap, the fatty acids rapidly partition into the outer
leaflet of the membrane. Because in such environment the
apparent pKa of the fatty acid shifts from 4.5 in an
aqueous solution to 7.6 (independent of fatty acid type),
about half of the fatty acids are present in the un-ionized,
i.e., protonated, form. This uncharged species can then
easily flip-flop without electrochemical restrictions to the
inner leaflet of the membrane, after which a proton is
donated to the interior solution and the fatty acid is
available for desorption (229). Applying this approach to
studies with phospholipid vesicles (230) and with adipo-
cytes (84, 228) revealed linear relationships between the
quantity of added fatty acids, the amount of fatty acids
that binds to the plasma membrane, and the decrease in
intracellular pH. From these various studies it was con-
cluded that binding of the fatty acid to the membrane
(adsorption) occurs extremely fast, seems to be diffusion-
limited, and is largely independent on the fatty acid chain
length, and that transbilayer movement is fast (t1/2 1 s)
for all fatty acid types and fast in cells (10 s). These
observations have been interpreted to infer that fatty
desorption from the membrane may be the rate-limiting
step for the overall transport rate of fatty acids, at least
for a protein-free model membrane (which represents an
FATTY ACID TRANSPORTERS AND LIPID METABOLISM 369
Physiol Rev • VOL 90 • JANUARY 2010 • www.prv.org
Downloaded from journals.physiology.org/journal/physrev at Universiteit Maastricht (137.120.149.252) on September 27, 2021.
artificial situation). A more recent study has provided
further evidence for this concept (383).
Kleinfeld and colleagues (97) used similar model sys-
tems to study transmembrane fatty acid transport, apply-
ing ADIFAB to detect fatty acid influx, to observe virtually
identical overall rates of transport as reported by Hamil-
ton’s group (228). However, in contrast to Hamilton, they
concluded that flip-flop is rate-limiting, since their data
showed that the dissociation of fatty acids from the mem-
brane is faster than flip-flop (97, 250). The discrepancies
with other reports have been attributed to 1) the absence
of albumin in some of these other studies which exposes
the membranes to high (5 M) concentrations of fatty
acids that perturb the bilayer structure, and 2) to misin-
terpretation of the measurements (233). More recently,
Kampf and Kleinfeld (232) have used quantitative fluores-
cence ratio microscopy to measure (noninvasively) fatty
acid transport into adipocytes by imaging the intracel-
lular (non-protein bound) fatty acid concentrations
(232). Their results indicate that transport rate con-
stants are 50-fold slower in adipocytes than in artifi-
cial phospholipid vesicles that contain no proteins,
such as are normally present in biological membranes.
From these data they conclude that fatty acid transport
across adipocyte membranes is highly regulated and
best described by a membrane carrier model (for re-
view, see Ref. 233).
In summary, studies in protein-free artificial mem-
branes show that passive flip-flop of the un-ionized form
of fatty acids can occur rapidly and in a protein-indepen-
dent manner across the lipid bilayer phase, indicating that
the lipid bilayer does not represent a barrier for fatty
acids (Fig. 1A). However, contrary to most findings with
these protein-deficient, synthetic lipid vesicles, newer
studies with cellular preparations that contain proteins
and which apply noninvasive techniques to monitor fatty
acid uptake, suggest that flip-flop is the rate-limiting step
for fatty acid transport across lipid bilayers (233, 234).
Because flip-flop is relatively slow and dependent on the
membrane structure (being slower through the ordered
phase than through the liquid-crystalline phase), diffusion
rates through the lipid bilayer may not be sufficiently
rapid to meet the metabolic demands of certain cells
and/or under certain conditions, particularly cells in
which the metabolic demands for fatty acids can be rap-
idly upregulated (e.g., heart and skeletal muscle). This
implies that at least certain biological tissues may require
membrane proteins to catalyze the flip-flop step (231).
Such proteins could act as transmembrane transporters
for fatty acids, but they could also attract albumin or
other fatty acid carriers and enhance the concentration of
fatty acids near the membrane surface, which would help
overcome the barriers of the unstirred water layer. Another
possibility is that membrane proteins act as a sink for fatty
acids, as has been proposed for caveolin-1 which has mul-
tiple basic residues at its intracellular domain that could
interact with the carboxylate anion and in this way acceler-
ate transmembrane fatty acid transport (see sect. IIID) (299).
A prevalent view is that both passive diffusion and
protein-mediated transport contribute to the cellular
uptake of fatty acids. Estimates of the contributions of
these two mechanisms have been made by deconvolu-
tion of uptake curves and by the use of inhibitors of
protein-mediated uptake. Because of saturation of the
protein-mediated component at high fatty acid concen-
tration, most of these studies have been interpreted to
suggest that protein-mediated uptake is important at
physiological concentrations of fatty acids and that
passive diffusion becomes predominant at higher, pre-
sumably nonphysiological concentrations of fatty acids
(2, 3). However, others feel that such data need to be
interpreted with caution (161). Still others have ques-
tioned the coexistence of diffusional and protein-mediated
fatty acid transport across the membrane’s lipid phase and
have proposed that fatty acid movement across the plasma
membrane is primarily protein mediated (232, 233).
Taken together, the unifying concept arises that
during the process of cellular uptake, fatty acids rapidly
bind and partition into the plasma membrane, then may
undergo lateral diffusion to specific domains such as
lipid rafts (333) before their desorption into the intra-
cellular compartment. Membrane proteins thus would
function in regulating fatty acid entry into the cell by
1) adsorbing fatty acids from the extracellular media
and modulating their transport into the membrane, and
2) segregating or organizing fatty acids for metabolism.
B. Evidence for the Involvement of
Membrane Proteins
Starting in the early 1980s, investigators from dif-
ferent laboratories reported that the uptake of fatty
acids into various parenchymal cell types showed
1) saturation kinetics, 2) sensitivity to general inhibi-
tors of protein-mediated plasma membrane transport
processes (e.g., phloretin and proteases), 3) sensitivity
to inhibition by nucleophilic fatty acid derivatives (e.g.,
sulfo-N-succinimidyloleate, SSO; later shown to specif-
ically inhibit CD36, see sect. IVA1), and 4) sensitivity to
competitive inhibition (5, 6, 287, 412). Although those
observations each are in favor of protein-mediated
transport, they have been disputed by others (161, 162,
358) who argued that saturation of fatty acid transport
can also be explained as saturation of metabolism in
combination with passive diffusion. Moreover, the used
inhibitors could theoretically inhibit fatty acid uptake via
indirect effects on the structural organization of the bilayer,
and the fatty acid competition experiments could unveil
competition for albumin rather than for transporters.
370 GLATZ, LUIKEN, AND BONEN
Physiol Rev • VOL 90 • JANUARY 2010 • www.prv.org
Downloaded from journals.physiology.org/journal/physrev at Universiteit Maastricht (137.120.149.252) on September 27, 2021.
On the other hand, when (both quiescent and con-
tracting) cardiac myocytes are subjected to increasing
concentrations of externally added fatty acids, uptake
becomes saturable while the intracellular fatty acid con-
centration remains low (287, 290). This observation indi-
cates that the metabolic machinery is easily capable of
trapping and metabolizing incoming fatty acids during
Vmax conditions and that saturation must come from up-
take. However, during fatty acid uptake, the major portion
of fatty acids is immediately esterified in both quiescent
(287) and contracting (290) cardiac myocytes, implying
that fatty acid uptake is closely coordinated with subse-
quent metabolism. For this latter reason, the introduction
of giant vesicles for the study of fatty acid transport was
a key methodological development (45, 286), as this of-
fered for the first time the means to examine the rates of
fatty acid transport in metabolically important mamma-
lian tissues in rodents (44, 45, 253, 272, 286) and in hu-
mans (48), independent of concurrent fatty acid metabo-
lism.
C
FIG. 1. A: putative molecular mechanism(s) for the cellular uptake
of long-chain fatty acids (FA) and of very-long-chain fatty acids (VLC-
FA). 1: In view of their hydrophobic nature, fatty acids could dissociate
from their albumin binding sites and cross the plasma membrane by
simple diffusion (referred to as uptake by passive diffusion). 2: Alterna-
tively, membrane-associated proteins, such as the peripheral membrane
protein FABPpm or the transmembrane protein CD36, could act, either
alone or together, as acceptor for fatty acids to increase their concen-
tration at the cell surface and thus enhance the number of fatty acid-
diffusion events. 3: CD36 itself may also facilitate the transport of fatty
acids across the phospholipid bilayer (uptake by facilitated diffusion).
Once at the inner side of the cell membrane, fatty acids are bound by
cytoplasmic FABP (FABPc) before entering metabolic or signaling path-
ways. 4: Additionally, a minority of fatty acids are thought to be trans-
ported by FATP1 and rapidly activated by plasma membrane acyl-CoA
synthetase (ACS1) to form acyl-Co esters. 5: VLC-FA are preferentially
transported by FATP1 (or other FATPs; see text) and by action of the
synthetase activity of FATP1 directly converted into VLC-acyl-CoA es-
ters (uptake by vectorial acylation). B: schematic presentation of the
proposed topology of CD36 (two transmembrane domains), with the
small cytoplasmic tails palmitoylated. The large extracellular loop has
10 putative N-linked glycosylation sites and two phosphorylation sites.
Disulfide bonds between the extracellular cysteines are also shown
(between amino acid residues 243–311, 272–333, and 313–323). The NH2
and COOH termini each contain two palmitoylation sites, and the COOH
terminus contains two ubiquitination sites. The shaded area designates
a hydrophobic pocket comprised by amino acid residues 93–183 that
likely is involved in ligand binding (residues 93–120 was identified as the
thrombospondin binding site, residues 120–155 was mapped for oxi-
dized LDL, and residues 139–183 form a multiligand binding site). Ar-
rowheads and numbers indicate the approximate positions of amino
acid residues. [Data compiled from Tao et al. (427), Febbraio and
Silverstein (125), Ibrahimi et al. (214), and Hoosdally et al. (205).]
C: proposed topology of FATP1. Only a short segment of the NH2
terminus faces the extracellular side of the membrane. Amino acid
residues 1–190 are integrally associated with the membrane, while
residues 190 –257 are cytosolic and contain the AMP-binding motif
that mediates the acyl-CoA synthetase activity. Amino acid residues
258 – 475 are peripherally associated with the inner leaflet of the cell
membrane. The COOH terminus is located in the cytoplasm. Arrow-
heads and numbers indicate the approximate positions of amino acid
residues. [Data compiled from Lewis et al. (266) and DiRusso et al.
(103).]
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Giant vesicles are formed from parenchymal cells by
incubation with an appropriate collagenase for that tissue
in a high K-containing buffer and are harvested by cen-
trifugation (295, 332). These vesicles have a size (10–15
m diameter) that is similar to that of small cells, are
oriented 100% right-side out, and contain soluble cytoplas-
mic constituents such as cytoplasmic FABP which will act
as a sink for fatty acids that have crossed the plasma
membrane (45, 253). Because of the absence of subcellu-
lar organelles or metabolic enzymes, giant vesicles can be
used to study substrate uptake dissected from metabo-
lism. Studies of the rate of fatty acid entry into rat heart-
and skeletal muscle-derived giant vesicles have provided
convincing evidence in support of the involvement of a
protein-mediated system. In these vesicles, the rate of
fatty acid (palmitate) entry is saturable, and inhibitable by
50–70% with protein-modifying agents (trypsin, phlor-
etin), reactive oleate esters, antisera to putative mem-
brane fatty acid transporters, and with other long-chain
(oleate) but not short-chain (octanoate) fatty acids (45,
286, 445). Among heart as well as red and white muscles,
the Km for vesicular fatty acid entry was similar (6–9 nM),
while the Vmax differed markedly and correlated with the
fatty acid oxidation capacities of these muscles (Fig. 2).
Together, these studies using rat tissue-derived giant ves-
icles also demonstrated that fatty acids traverse the
plasma membrane in heart and skeletal muscle largely via
a protein-mediated system, one that is scaled with the
capacity to metabolize fatty acids in these tissues.
Although giant plasmalemmal vesicles offer the ad-
vantage of conducting substrate uptake studies in meta-
bolically important tissues such as heart, skeletal muscle,
adipose tissue, and liver from rodents (41, 44, 45, 253, 273,
286) and human skeletal muscle (48), this model system
also has some limitations. For instance, specific subplas-
malemmal domains may not be included in the vesicle
preparation. Specifically, t tubules are completely ex-
cluded, while it is known that substrate transport proteins
such as GLUT4 are present in t tubules (261, 264). In
addition, caution should be taken with the interpretation
of experimental data from studies with vesicles from
distinct tissues. For instance, in heart and muscle, the
driving gradient for net fatty acid movement is always
from the extracellular space into the myocyte, while in
adipose tissue fatty acid transport may be directed into or
out of adipocytes. Therefore, in view of their distinct
metabolic functions, muscle tissues (heart and skeletal
muscle) and adipose tissue cannot serve as interchange-
able model systems for examining the regulation of fatty
acid transport (39).
It should be noted that the Km for vesicular fatty acid
entry into heart and skeletal muscle (Km  6–9 nM; Refs.
44, 45, 286) is similar to the extracellular or circulating
concentration of (non-protein bound) fatty acids (7.5
nM; see sect. IIA). Such a close relationship also exists
between the transport capacities of the glucose trans-
porter GLUT4 and the lactate transporter MCT1 with their
circulating substrate concentrations in vivo, i.e., GLUT4
Km  4.3 mM (316) and plasma glucose 4–5 mM, MCT1
Km  3.5 mM and plasma lactate 1–2 mM (55). Thus, for
substrate transport, it seems to be a general principle that
the Km of substrate transporters is closely matched to
circulating substrate concentrations. This is advanta-
geous, as this allows for highly sensitive protein-mediated
transport of circulating substrates, including fatty acids.
In summary, there is a clear role for membrane pro-
teins in the cellular uptake of fatty acids. Although the
exact mechanism of transmembrane transport of fatty
acids remains largely unknown, i.e., diffusional transbi-
layer movement of fatty acids in the membrane may occur
independently or as part of a protein mediated process,
properties of both the lipid bilayer and the fatty acid
FIG. 2. Characterization of fatty acid transport into giant sarcolemmal vesicles obtained from heart and skeletal muscle. A: kinetics of palmitate
transport into giant sarcolemmal vesicles from rat heart and red and white skeletal muscle. B: correlation between the rate of palmitate transport
into giant sarcolemmal vesicles and the amount of the fatty acid transporter CD36 located on the plasma membrane of these vesicles. C: correlation
between the rate of palmitate transport into giant sarcolemmal vesicles and the fatty acid oxidation capacities of the tissues. [Redrawn from studies
by Bonen et al. (45), Glatz et al. (144), and Luiken et al. (286).]
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binding membrane proteins each will influence the uptake
process. The presence of an intracellular fatty acid recep-
tor beyond the cell membrane, such as FABPc, is critical
(280). This may explain why in certain cell lines an in-
creased presence of fatty acid transporters in the cell
membrane did not increase fatty acid uptake (118, 458,
460). Such concern does not apply to glucose uptake
because of its miscibility in the cytoplasm.
III. MEMBRANE-ASSOCIATED FATTY
ACID TRANSPORTERS
The early observations of saturation kinetics of fatty
acid transport (5, 6, 412) already triggered the search for
membrane proteins that act as fatty acid transporters
(172–174, 371, 413–416, 437, 438). Since then, different
groups have identified integral and peripheral membrane
proteins that appeared to be involved in the transport of
fatty acids into parenchymal cells. For convenience, these
proteins are commonly referred to as “fatty acid trans-
porters,” despite the remaining uncertainty as to the exact
mechanism by which any one of these proteins partici-
pates in the transport process within the plasma mem-
brane. Table 1 provides a listing of putative fatty acid
transporters identified to date, together with their occur-
rence. Strikingly, these proteins differ in molecular mass
and degree of posttranslational modification; some show a
characteristic pattern of tissue distribution, while others are
ubiquitously expressed. Interestingly, the FATPs form a fam-
ily of six proteins. Support for facilitating long-chain fatty
acid transport by each of these differing transporters (with
the exception of caveolin-1) has been obtained from genetic
studies in cell lines [plasma membrane-associated FABP
(FABPpm) (217), CD36 (214), FATP1-6 (104, 159, 160, 268)],
as well as from studies in tissues of genetically altered
animals [FABPpm (85, 200, 315), CD36 (42, 86, 123, 153),
FATP1 (80, 479), FATP4 (315)].
A. Plasma Membrane Fatty Acid Binding Protein
In mammalian tissues, FABPpm was originally identi-
fied by Stremmel et al. in rat liver (416) and jejunal
microvilli (414), and later in adipose tissue (336, 378) and
cardiac myocytes (393, 411), all of which are cells with
high transmembrane fluxes of fatty acids. FABPpm is pe-
ripherally bound at the outer leaflet of the plasma mem-
brane, as FABPpm from rat liver could be isolated by a
high-ionic-strength medium (394). Antibodies directed
against rat liver FABPpm were found to inhibit fatty acid
uptake by hepatocytes (415, 416), jejunal microvilli (414),
adipocytes (378), cardiomyocytes (393, 411), and cardiac
and skeletal muscle-derived giant vesicles (286, 445) by
50–75%. This suggested that at least a substantial portion
of overall fatty acid uptake involved the binding of fatty
acids by FABPpm and that the same, or a very similar,
protein is expressed in these distinct tissues. In addition,
these studies do not rule out the contributions of other
TABLE 1. Membrane-associated putative fatty acid transporters
Protein (Current Designation) Molecular Mass, kDa Tissue Occurrence Key Reference Nos.
Plasma membrane fatty acid binding
protein (FABPpm)
40–43 Liver, heart, muscle, adipose tissue,
intestine, placenta
26, 63, 85, 217, 378, 411, 414, 416,
419
FA transport protein (FATP) 63
FATP1 Adipose tissue, heart, muscle, brain, kidney,
skin, lung
181, 185, 191, 219, 315, 371, 375
FATP2 Kidney, liver, intestine 183, 190, 191, 226, 366
FATP3 Lung, liver, testis, skin 191, 328, 375
FATP4 Intestine, brain, kidney, liver, skin, lung,
heart, skeletal muscle
107, 153, 181, 185-187, 191, 219,
315, 375
FATP5 Liver 105, 191, 209
FATP6 Heart, skeletal muscle, placenta, testis,
adrenal glands, kidney, bladder, uterus,
skin
139, 181, 219, 375
Fatty acid translocase/CD36 88* Heart, intestine, skeletal muscle, adipose
tissue, spleen, platelets,
monocyte/macrophage, endothelium,
epidermis, kidney, brain, liver
4, 124, 150, 272, 273, 294, 375, 459
Caveolin-1 21–24 Ubiquitously expressed, except in muscle
and heart where caveolin-3 is
predominantly expressed
333, 335, 436
The designation “fatty acid transporter” is used for convenience but does not necessarily imply a classic transmembrane transport mechanism
such as that of GLUT4. The proteins share the feature of facilitating the transmembrane translocation of (long-chain) fatty acids, although the role
of caveolins in fatty acid transport remains controversial (see sect. IIID). Tissue occurrence refers to tissues for which the expression (mRNA or
protein) was reported. Relative occurrence is not always clear, as this may differ across species and will depend among other things on
developmental and nutritional status, muscle and cardiac activity, and health status. *Glycosylated protein mass. The mass of the nonglycosylated
protein is 53 kDa. Glycosylation may differ in some tissues, such as mammary gland, where CD36 molecular mass is 75 kDa.
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fatty acid binding proteins, as inhibition of fatty acid
transport by FABPpm antibodies was incomplete.
Analysis of its amino acid sequence showed FABPpm
to be identical to the mitochondrial aspartate aminotrans-
ferase (mAspAt) (26, 419). FABPpm and mAspAt are de-
rived from the same gene while not requiring alternative
splicing of the mRNA (51). Apparently, FABPpm/mAspAt
is a protein with distinct functions at different subcellular
sites. In Xenopus laevis oocytes (484), 3T3 fibroblasts
(217), and rat skeletal muscle (85, 200), transfected with
mAspAt cDNA, FABPpm/mAspAt was localized both to the
mitochondria (200) and to the plasma membrane (85, 200,
217, 484). This increased the rates of fatty acid transport
into giant sarcolemmal vesicles obtained from skeletal
muscle (85, 200). However, the relative increase in plas-
malemmal FABPpm (173%) was far in excess of the
increase in fatty acid transport (79%) (85), suggesting
that the transport capacity of FABPpm alone is perhaps
modest.
1. Effects of FABPpm on fatty acid metabolism
FABPpm overexpression in skeletal muscle did not
alter triacylglycerol formation, but fatty acid oxidation
was increased (85, 200). This was attributable to addi-
tional fatty acids transported into the muscle cell, as the
concurrent overexpression of FABPpm/mAspAt in mito-
chondria did not alter fatty oxidation by isolated mito-
chondria (200; see also sect. IVB). There is some evidence
for cooperation of FABPpm with other fatty acid trans-
porters, specifically CD36 (see sect. IVA) (75). Ablation
studies of FABPpm/mAspAt have not yet been performed.
B. Fatty Acid Translocase/CD36
Studies by Abumrad and co-workers on the inhibi-
tory action of reactive sulfo-N-succinimidyl esters of long-
chain fatty acids (SSO, see sect. IIB) on fatty acid uptake
by rat adipocytes (172–174) led to the identification of an
integral membrane protein designated (putative) mem-
brane fatty acid translocase (4) that appeared identical to
leukocyte cluster-of-differentiation antigen CD36 (glyco-
protein IV), now recognized as a class B scavenger recep-
tor protein with multiple functions, particularly the bind-
ing of thrombospondin, oxidized low-density lipoprotein
(LDL), and anionic phospholipids, and its action as a
gustatory lipid sensor (124, 125, 212, 241, 417, 420). CD36
is a 472-amino acid (53 kDa) protein that has a hairpin
membrane topology with two transmembrane spanning
regions, with both the NH2 and COOH termini as short
segments in the cytoplasm (427) (Fig. 1B). The NH2-
terminal hydrophobic domain appears to serve as a trans-
membrane anchor (427). The protein is heavily glycosy-
lated (10 predicted N-linked glycosylation sites situated in
the large extracellular loop), has two phosphorylation
sites (Thr-92 and Ser-237) and three external disulfide
bridges, and contains four palmitoylation sites (225, 427),
two each at the extreme NH2 and COOH termini (cys-
teines 3, 7, 464, and 466) (see sect. IVB1). The COOH-
terminal domain also contains two ubiquitination sites
(Lys-469 and Lys-472) (see sect. IVB3). Studies in rat hep-
atoma cells suggest that the COOH-terminal YCAR motif
is required for CD36 localization to the cell surface and to
enhance long-chain fatty acid uptake (119).
The extensive glycosylation increases the apparent
mass of CD36 from 53 to 88 kDa (Table 1). However, it
was recently shown that mature glycosylation is not nec-
essary for surface expression of CD36 in mammalian cells
(205). CD36 is associated with the cholesterol- and sphin-
golipid-rich membrane microdomains known as rafts (or
as caveolae when they contain caveolin). The role of
caveolae in CD36 functioning is discussed in section IIID.
Whether caveolins are involved in targeting CD36 to the
plasma membrane is not entirely clear given some con-
tradictory evidence among studies in the heart (14, 15),
mouse embryonic fibroblasts (354), and 3T3-L1 fibroblasts
and adipocytes (333, 334). Alternatively, palmitoylation of
each of the cytoplasmic tails could help recruit CD36 to
these membrane microdomains. In this respect, palmi-
toylation is often involved in regulation of intracellular
trafficking and localization of membrane proteins (re-
viewed in Ref. 149), especially in the trafficking of these
proteins to lipid rafts and/or caveolae.
CD36 is ubiquitously expressed in many tissues, as
well as endothelial cells, platelets, and macrophages, and
is involved in angiogenesis, atherosclerosis, inflammation,
and lipid metabolism (for review, see Refs. 124, 125).
In vitro studies showed that CD36 purified from adipose
tissue binds long-chain but not short-chain fatty acids (16,
225). A key role for CD36 in fatty acid transport was
demonstrated when Ob17PY fibroblasts (214), C2C12 fi-
broblasts (20), and skeletal muscle (315) were transfected
with CD36, which resulted in increased rates of fatty acid
uptake. However, others have found that transfecting
CD36 into CHO cells fails to increase fatty acid uptake
under basal conditions (118, 460) or when insulin was
used to increase plasmalemmal CD36 (460), suggesting
that in these cells, such an increase requires additional
proteins, or a protein activation step. CD36 is also re-
quired both for the uptake of very-long-chain fatty acids
(VLCFAs) in cultured cells and for the intestinal absorp-
tion of dietary VLCFAs in mice (110). CD36 can also
function as a cell adhesion molecule or as a class B
scavenger receptor (124, 125). Finally, CD36 appears to be
a selective and nonredundant sensor of microbial diacyl-
glycerides (192). This CD36 versatility for a wide variety
of ligands may possibly be due to differences in the
glycosylation of the protein and/or specific interaction
with other proteins or membrane constituents.
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1. Effects of CD36 on basal fatty acid metabolism
Under basal conditions, a null mutation in murine
CD36 reduced the uptake of the fatty acid analogs 15-(p-
iodophenyl)-3-(R,S)-methyl pentadecanoic acid (BMIPP)
and 15-(p-iodophenyl)pentadecanoic acid (IPPA) in vivo
in heart (	50 to 	80%), skeletal muscle (	40 to 	75%),
and adipose tissue (	60 to 	70%) (86). CD36 null mice
did not show alterations in fatty acid uptake by the liver
(86), an organ with absent or very low CD36 expression
(123, 253, 272). Comparable reductions were also ob-
served in studies using a naturally occurring fatty acid
(palmitate) in CD36 null skeletal muscles (	23%) (42),
but not in CD36 null cardiac myocytes (153), presumably
due to the compensatory twofold overexpression of
FATP1 in CD36 null cardiac myocytes (153).
In perfused, CD36-null murine muscles, the basal
rates of fatty acid oxidation (	26%) and triacylglycerol
formation (	38%) were reduced (42). Similarly, in CD36
null cardiac myocytes, there was a 25% reduction in fatty
acid oxidation (216), which was restored by transgenic
rescue of CD36 (216). There were also reductions in
intracellular triacylglycerol concentrations in perfused
CD36 null hearts (	27 to 	64%; Refs. 86, 216) and in
skeletal muscle (	70%; Ref. 86). This was likely due to a
reduction in the basal rate of triacylglycerol esterification
in CD36 null mice (	38%, in red muscles; Ref. 42). In
contrast to these studies in CD36 null mice, no changes
in basal rates of fatty acid metabolism were observed in
isolated soleus muscles of CD36-overexpressing mice
(213), presumably since rates of fatty acid metabolism are
low in isolated muscle that are at complete rest (see
below).
2. Effects of CD36 on fatty acid metabolism during
metabolic challenges
Examining the role of CD36 on fatty acid metabolism
under basal conditions has underestimated its role in
regulating fatty acid uptake and metabolism. Metabolic
challenge studies have now been performed in isolated
muscles of CD36 overexpressing mice (213) and in hind-
limb muscles (42), hearts (258), and cardiac myocytes
(153) of CD36 null mice, using stimuli that are known to
increase triacylglycerol formation (insulin, Refs. 91, 115,
278) and/or fatty acid oxidation (contraction, AICAR, oli-
gomycin, working heart, Refs. 213, 277, 385, 386), as well
as inducing the translocation of CD36 to the plasma mem-
brane in these tissues (44, 73, 91, 277, 278) (see sect. IVA).
In cardiac myocytes and in perfused skeletal muscles
of CD36 null mice, stimulation of fatty acid uptake by
oxidation-enhancing agents was markedly impaired [car-
diac myocytes: wild type (WT) 150%; knock out (KO)
20% (153); skeletal muscle: WT 77%, KO 13% (42)],
while insulin stimulation of fatty acid uptake was also
markedly impaired in muscle of CD36 null mice (21%)
compared with WT mice (60%) (42). These reductions in
fatty acid uptake also contributed to altered rates of fatty
acid metabolism. For example, in working hearts, fatty
acid oxidation remained 40–60% lower in CD36 null than
in WT mice (254, 258), and in CD36 null muscle, AICAR-
stimulated fatty acid oxidation was also markedly im-
paired (KO 38%; WT 100%; Ref. 42). Conversely, in
CD36 overexpressing mice, muscle contraction increased
fatty acid oxidation by 400%, while in WT mice, the
increase was much less, i.e., 100%. Insulin-stimulated
triacylglycerol esterification in CD36 null red muscle
(34%) was increased much less than in red muscles of
WT mice (70%) (42). Since the cellular signaling path-
ways and enzymatic activities are not altered in CD36 null
mice (42, 86, 153), these studies demonstrate that CD36
contributes markedly to the regulation of fatty acid oxi-
dation and esterification in heart and skeletal muscle,
particularly during metabolic challenges.
C. Fatty Acid Transport Proteins
Schaffer and Lodish (371) used an expression cloning
strategy to identify a protein that, when expressed in
COS7 cells, increased the uptake of fluorescently labeled
fatty acids. This 646-amino acid fatty acid transport pro-
tein (FATP; recently renamed as FATP1) is an integral
membrane protein that has six membrane-spanning re-
gions. Subsequently, others disclosed the existence of a
family of integral membrane FATPs, referred to as
FATP2-6 (139, 191). These FATP isoforms are expressed
in somewhat of a tissue-specific manner (Table 1) (107,
469).
FATP1 contains a hydrophobic NH2-terminal region
(residues 1–190) that is integrally associated with mem-
branes, whereas amino acid residues 258–313 and 314–
475 are only peripherally membrane associated, and res-
idues 191–257 and 476–646 do not direct membrane as-
sociation and likely face the cytosol (266) (Fig. 1C). The
mechanism of action for FATP1 involves ATP binding that
is dependent on serine-250 of the IYTSGTTGXPK motif
(residues 247–257) (347, 418). FATP1 may also form de-
tergent-resistant dimers that have a functional role in fatty
acid transport (347). The region between amino acid res-
idues 191–475 is sufficient to allow an association of
FATP1s (347). Both the monomeric (63 kDa) and oligo-
meric forms (130 kDa) are present in NIH 3T3 cells
(347).
FATP1 is expressed in many tissues, including brain,
kidney, lung (191), skin (375), adipose tissue (107), heart
(73, 80, 107, 139, 153, 181), and skeletal muscle (42, 46,
107, 219, 315) (Table 1). FATP2 is expressed primarily in
liver and kidney (183, 191, 226, 366) as well as in the
intestines (190), whereas FATP3 has a more restricted
distribution being expressed in liver, lung, testis, and skin
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(191, 328, 375). FATP4 is expressed in intestine, brain,
kidney, liver, skin, lung, heart, and skeletal muscle (107,
153, 181, 185–187, 191, 219, 315, 375). In contrast, FATP5
is only expressed in liver (105, 191, 209). Finally, although
FATP6 was deemed to be heart specific (139), this protein
is expressed in a number of other tissues, including skel-
etal muscle, placenta, testis, adrenal glands, kidney, blad-
der, uterus, and skin (139, 181, 219, 375).
1. Fatty acid transport roles of FATPs
Expression of the murine FATPs in a genetically
defined yeast strain increased fatty acid transport with
varying degrees of effectiveness. FATP1, -2, and -4 are
particularly effective in facilitating the rates of long-chain
fatty acid transport by 8.2-, 4.5-, and 13.1-fold, respec-
tively, whereas FATP3 and -5 provide only a modest 2-fold
increase, and FATP6 provides virtually no increase in
long-chain fatty acid transport (104). However, studies in
other models suggest somewhat different fatty acid trans-
port roles for FATPs. In MA-10 Leydig cells, FATP3 ex-
pression failed to alter fatty acid transport (328). Knock-
down studies of FATP1 (3T3-L1 adipocytes) revealed that
basal fatty acid uptake was reduced (268), whereas with
FATP4 knockdown (3T3-L1 adipocytes) or overexpres-
sion (HEK-293 cells), there were no changes in fatty acid
uptake (268). Another study has indicated that FATP4 is
not present at the plasma membrane and is not a fatty
acid transporter in a wide variety of cultured cells (300).
In contrast, experiments in rat skeletal muscle indicated
that FATP1 and -4 have fatty acid transport function, with
FATP4 being more effective than FATP1 (315), as was
also observed in yeast (104). Others have shown that the
transport capacity of FATPs in 293 cells depends on the
fatty acid used (palmitate transport: FATP6  FATP1 
FATP4; oleate transport: FATP4  FATP1  FATP6)
(139), suggesting that different FATPs transport specific
fatty acids with different efficiencies. Thus the claim that
FATP6 is the most important fatty acid transporter in the
heart (139) is premature. Interestingly, in vitro FATP5
from liver exhibits both fatty acid transport and bile acid-
CoA ligase activity (104, 107, 191, 209).
The differing transport capacities for the same FATP
isoform among several studies may indicate that there
may well be cell-type specific responses, whereby the
functioning of the FATP isoforms may depend on the
presence and/or interaction with other proteins or mem-
brane constituents. Therefore, some care is required
when using cultured cell lines to extrapolate the function
of FATPs and other fatty acid transporters to the in vivo
situation in mammalian tissues, as all the necessary bio-
chemical transport and/or trafficking machinery normally
present in mammalian tissues may be incomplete in se-
lected cell lines, as has been suggested in several recent
studies (118, 460).
To elucidate the in vivo roles of the FATPs, genera-
tion of transgenic mice has been undertaken for FATP1,
-4, and -5. Cardiac-specific overexpression (8-fold) of
FATP1 increased the rate of fatty acid uptake (4-fold)
(80). In contrast, ablation of FATP1 did not reduce basal
rates of fatty acid uptake, either in adipocytes or in skel-
etal muscle (479). Combined, these findings may indicate
that FATP1 is a functionally important fatty acid trans-
porter but only at nonphysiologically high expression lev-
els, and that at normal expression levels it contributes
minimally to the bulk uptake of fatty acids in muscle
tissues. Nevertheless, during metabolic challenges, the
role of FATP1 might become more important, as it was
reported that insulin-stimulated fatty acid uptake is mark-
edly reduced in FATP1 null muscle (479). Deletion of one
allele of FATP4 resulted in 48% reduction of FATP4 pro-
tein levels and a 40% reduction of BODIPY-fatty acid
uptake by isolated enterocytes, but did not affect intesti-
nal fat absorption either with normal diet or with a high-
fat diet (138). Deletion of both FATP4 alleles resulted in
early embryonic lethality (138, 187), possibly as a result of
reduced fat absorption in association with FATP4 dele-
tion from the epithelial cells of the visceral endoderm and
the brush-border membrane of extraembryonic endoder-
mal cells, as well as neonatally lethal restrictive dermop-
athy (187). In epidermal keratinocytes, FATP4 is essential
for the maintenance of a normal epidermal structure
(186). FATP5 null mice showed a decreased fatty acid
uptake rate (	50%) in primary hepatocytes and reduced
hepatic fatty acid and triacylglycerol contents (105).
Knockdown of hepatic FATP5 in vivo resulted in a
marked reduction of hepatic dietary fatty acid uptake,
reduced caloric uptake, and concomitant protection from
diet-induced nonalcoholic fatty liver disease (106). Defec-
tive bile acid conjugation, which relates to the bile acid-
CoA synthetase activity of FATP5, has been observed in
FATP5 null mice (209).
2. Very-long-chain acyl-CoA synthetase activity
of FATPs
In early studies on FATPs, it was found that these
proteins shared considerable sequence homologies and
domain organization to acyl-CoA synthetases, suggesting
that FATPs are members of the superfamily of adenylate
forming acyl-CoA synthetases, particularly very-long-
chain acyl-CoA synthetases (VLACS) for C22 (120, 371,
470, 471). However, in vivo very-long-chain fatty acids
constitute only a small fraction of the total fatty acid pool.
For example, in dogs fatty acids C22 constitute 0.5% of
the circulating fatty acids and 1.8% of the triacylglycerol
fatty acids (456). Circulating fatty acids and triacylglycer-
ols are largely comprised (90%) of long-chain (C16:0-
C18:2) fatty acids in dogs (456) and rodents (145), and this
is also reflected in the makeup of intramuscular lipids
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(145, 456). These observations would seem to imply that
very-long-chain fatty acids are relatively unimportant sub-
strates for cardiac and skeletal muscle energetics and that
the VLACS function of FATP1 would not mediate the
transport function for long-chain (C14:0-C18:1) fatty ac-
ids. Indeed, there is only a limited sequence similarity
between FATP1 and the multigene family of long-chain
acyl-CoA synthetases (ACS) for these abundant long-
chain (C14:0-C18:1) fatty acids. Nevertheless, the concern
remained that the fatty acid transport function of FATP
was due to the rapid esterification of fatty acids to CoA
thioesters by acyl-CoA synthetase (a process known as
vectorial acylation; Refs. 249, 323), as this would serve to
increase the fatty acid concentration gradient across the
plasma membrane by removing fatty acids once they have
traversed the plasma membrane. A similar process of
metabolic trapping by the hexokinase-catalyzed phos-
phorylation of glucose has long been recognized. Al-
though the overexpression of FATPs increases the activ-
ity of long-chain and very-long-chain fatty acyl-CoA syn-
thetases (87, 120, 185, 448, 486, 487), it is doubtful that
VLACS activity accounts for the transport of long-chain
fatty acids (159, 160, 486) because for the most abundant
circulating fatty acids (C:14-C:18), the acyl-CoA syn-
thetase activity is either very low (FATP1), or alterna-
tively, in vivo, these fatty acids are not preferred (FATP4).
3. Long-chain acyl-CoA synthetases
Expression of fatty acyl-CoA synthetases that are
unrelated to the FATP-associated VLACS can enhance
fatty acid uptake in Escherichia coli (292, 373, 472), yeast
(432), and 3T3-L1 adipocytes (136, 346), suggesting that
vectorial acylation may drive fatty acid transport. In
3T3-L1 adipocytes, ACS1 is an integral membrane protein
which colocalizes and interacts with FATP1 (136, 346).
Overexpression of each of these two proteins increases
fatty acid uptake, and their concomitant overexpression
has a synergistic effect on fatty acid uptake (136), while
blocking ACS1 activity reduces fatty acid uptake (346).
However, these studies (136, 292, 346, 373, 432, 472)
should not be taken to imply that the formation of fatty
acyl-CoAs (vectorial acylation) obviates the need for a
fatty acid transport mechanism. Instead, fatty acid trans-
port and ACS1 activity are most likely complementary
processes, comparable to that of GLUT4-facilitated glu-
cose transport and hexokinase II activity in vivo (130–
135). Indeed, in skeletal muscle, the coordinated expres-
sion of CD36 and ACS1 in red and white muscles, and in
chronically stimulated muscles (r  0.98) is an example
of functional complementarity between these proteins, as
this allows a greater rate of fatty acids to be transported
into the muscle cell via CD36, which can then be activated
by ACS1 (279).
The independence of fatty acid transport from vectorial
acylation has been shown in a number of studies. First, with
giant vesicles there is no evidence for any fatty acid metab-
olism, because incoming fatty acids were retrieved as fatty
acids in the vesicular lumen, most likely bound to cytoplas-
mic FABP (45, 286). Second, studies by DiRusso et al. (104)
have resolved some of the confusion concerning the fatty
acid transport functions and acyl-CoA synthetase activities
of FATPs. Expression of the murine FATP1-6 in a genetically
defined yeast strain, which normally cannot transport long-
chain fatty acids, and which has a reduced VLACS activity,
demonstrated the independent fatty acid transport capaci-
ties from the VLACS activity of many of these FATP iso-
forms. Specifically, FATP1-5 expression, but not FATP6,
increased fatty acid transport differentially, i.e., 2.3-fold
(FATP3 and -5), 4.4-fold (FATP2), 8-fold (FATP1), and 13-
fold (FATP4). Concomitantly, these proteins only marginally
altered oleoyl-CoA synthase activity (104) while, except for
FATP5, VLACS activity was increased for all other FATPs
(range 2- to 24-fold; Ref. 104). Thus FATP isoforms appear to
play unique roles in fatty acid trafficking, including the trans-
port of exogenous long-chain fatty acids (FATP1-5) and
very-long-chain fatty acid activation (FATP1-4, -6). Impor-
tantly, these studies also demonstrated that the fatty acyl
activation function of FATPs is not required for long-chain
(C:14-C:18) fatty acid transport (104).
In summary, it appears that the fatty acid transport
function of FATPs is not attributable to their FATP-asso-
ciated VLACS activity, which is very low compared with
ACS1 activity. Moreover, ACS1 activity by itself also does
not account for fatty acid transport. Instead, in vivo,
FATPs, and likely other fatty acid transporters, act in a
concerted fashion with ACS1 as functional complex, to
take up and activate fatty acids, thereby maintaining an
effective transplasmalemmal fatty acid gradient and cou-
pling fatty acid transport to its metabolism.
D. Caveolins
Caveolins are the defining protein constituents of
caveolae, which are specialized microdomains of the
plasma membrane, enriched in cholesterol, sphingomy-
elins, and signaling and receptor proteins (88, 327).
Caveolins are responsible for the invagination of the
plasma membrane, giving the caveolar microdomains
their flask-shaped appearance. They are small integral
membrane proteins (22 kDa) with an additional hydro-
phobic scaffolding domain for binding to other proteins.
Currently, three members of the caveolin family have
been identified. Caveolin-1 and -2 have a relatively ubiq-
uitous distribution pattern in mammalian tissues with the
exception of muscle tissues, whereas caveolin-3 is the
predominant isoform in muscle and heart (88, 148).
Unexpectedly, a screen for high-affinity fatty acid
binding proteins within adipocyte plasma membranes us-
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ing photoreactive fatty acid analogs yielded a single pro-
tein of 22 kDa, subsequently identified as caveolin-1 (436).
This raised the notion that next to its caveolar-related
functions, caveolin-1 could serve as a fatty acid trans-
porter.
Studies by Pohl and colleagues (333, 335) on the role
of caveolae in the uptake of fatty acids in HepG2 and 3T3
cells using cholesterol-depleting agents, caveolin-1 anti-
sense oligonucleotides or caveolin dominant-negative mu-
tants revealed an up to 50% inhibition of fatty acid uptake
by these treatments. Interestingly, caveolae also contain
CD36, suggesting that CD36 is involved in caveolae-medi-
ated fatty acid uptake (333). This notion gained further
credence by the observation that caveolin-1 ablation in
fibroblasts reduced the plasma membrane content of
CD36 in parallel with a reduction of cellular fatty acid
uptake (354). Conversely, caveolin-1 overexpression redi-
rected CD36 to the plasma membrane and rescued fatty
acid uptake (354). Whereas the initial experiments with
photoreactive fatty acid analogs revealed caveolin-1 to be
a potential fatty acid transporter (436), the latter experi-
ments (354) indicate that caveolins function in fatty acid
uptake in an indirect manner, i.e., by offering plasma
membrane docking sites for CD36.
It should be noted, however, that this CD36-assisting
function of caveolin-1 (and -3) was questioned in other
studies, because 1) overexpression of caveolin-1 is able to
modulate fatty acid uptake in HEK-293 cells which do not
express CD36 (299, 382), 2) cholesterol depletion in adi-
pocytes reversibly inhibited fatty acid uptake without
altering the cell surface localization of caveolin-1 or
CD36 (95), and 3) in hearts of caveolin-1 null mice in
vivo, there was an increase in fatty acid uptake (47%)
(15). These conflicting conclusions about the coopera-
tion between caveolin-1 and CD36 in cellular fatty acid
uptake may relate to tissue-specific or cell-specific dif-
ferences, or may be due to the different methods and/or
the model systems used. Hence, fine-tuning of these
studies is needed to assess the role of caveolin-1 in
cellular fatty acid uptake.
With respect to caveolin-3, the predominant isoform
in muscle and heart, this protein was found to be colo-
calized with CD36 at the sarcolemma (236, 464). While
this colocalization suggests that in muscle tissues caveo-
lin-3 might assist CD36 in fatty acid uptake, studies in
hearts of caveolin-3 knockout mice did not reveal any
changes in cardiac fatty acid uptake and metabolism (14).
Taken together, the functioning of members of the caveo-
lin family as fatty acid transporters is still controversial.
E. Overall Conclusions on Fatty Acid Transporters
Genetic studies in vitro and/or in vivo have greatly
helped in establishing the roles of FABPpm, CD36, FATPs,
and caveolins in cellular fatty acid uptake. One remark-
able issue is that all fatty acid transporters also appear to
have functions that are unrelated to fatty acid transport;
for example, FABPpm and the FATPs contain mAspAt
activity and VLACS activity, respectively; CD36 displays
multiple other functions, including thrombospondin bind-
ing; caveolins possess the ability to form caveolar regions.
This notion should not be taken to preclude a significant
role for these proteins in the regulation of fatty acid flux
across the plasma membrane. Importantly, there are nu-
merous unresolved issues concerning the fatty acid trans-
porters: 1) their three-dimensional protein structure and
membrane topology; 2) their specific mode of action in-
cluding possible interactions with each other and with
other proteins; 3) their possible substrate specificity, i.e.,
the relative affinity towards saturated versus unsaturated
and polyunsaturated fatty acid species; and 4) their ability
to couple fatty acid uptake to channeling into distinct
metabolic pathways (see sect. IVD). Moreover, the listing
of fatty acid transporters may not be complete, as sugges-
tions have been made that other fatty acid proteins may
yet be identified (cf. Ref. 234). Finally, as mentioned
above (see sect. IIB), caution should be taken by using any
one cell type or mammalian tissue as a universal model
for fatty acid transport or transporters. In view of the
distinct metabolic roles of selected tissues and differ-
ences in bidirectional (adipose tissue) and monodirec-
tional (heart, muscle, liver) transmembrane fatty acid
fluxes, the expression and functioning of the various fatty
acid transporters may well be quite dissimilar.
IV. FUNCTIONING AND SUBCELLULAR
LOCALIZATION OF FATTY
ACID TRANSPORTERS
The studies reviewed in the previous section have
established that a number of distinct membrane pro-
teins facilitate the transport of fatty acids across the
plasma membrane. Insight into the functioning and
physiological significance of these fatty acid transport-
ers was obtained from studies in which it was shown
that fatty acid transporters can traffic between intra-
cellular depots, and the plasma membrane and mito-
chondria in response to physiological perturbations
(muscle contraction, exercise, insulin), and from stud-
ies on posttranslational modification of fatty acid trans-
porters, as will be outlined below.
A. Subcellular Translocation of Fatty
Acid Transporters
The observation that muscle-specific overexpression
of CD36 increased fatty acid uptake only during muscle
contraction (213) triggered us to investigate the possibil-
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ity that in response to muscle contraction CD36 would
translocate from a putative intracellular storage site to the
sarcolemma to increase fatty acid uptake. Such a mech-
anism would resemble the well-known regulation of mus-
cle glucose uptake by subcellular translocation of GLUT4
(for review, see Refs. 99, 208, 362, 365, 428).
1. Contraction-mediated regulation of fatty acid
transport and transporters
The first evidence that fatty acid uptake was regu-
lated acutely at the level of the plasma membrane was
obtained from studies in which the metabolic demands
of skeletal muscle in vivo were increased via electri-
cally induced contraction (44). Almost immediately
with the onset of muscle contraction there was an
increase in the rate of fatty acid transport into giant
sarcolemmal vesicles prepared from these muscles
(20 –29% after 1–5 min) with a maximal 1.8-fold in-
crease being attained after 30 min. Upon cessation of
muscle contraction for 20 min, rates of fatty acid trans-
port returned to basal rates. The contraction-induced
increases in fatty acid transport rates were linearly
related with the intensity of the muscle contraction,
indicating that fatty acid uptake into muscle scaled
with the muscles’ metabolic demands. These studies
also revealed for the first time that the contraction-
induced increase in fatty acid transport was accompa-
nied by a concurrent translocation of a fatty acid trans-
porter, CD36, from an intracellular depot to the plasma
membrane (1.4-fold) and the reinternalization of this
transporter with the cessation of muscle contraction
(Fig. 3) (44). All this was highly reminiscent of contrac-
tion-stimulated GLUT4 translocation and glucose trans-
port described a decade earlier (for review, see Ref.
362). Since the contraction-induced fatty acid transport
was inhibited by the specific CD36 inhibitor SSO, which
binds covalently to CD36 (44, 92, 153), a central phys-
iological role for this fatty acid transporter was estab-
lished (Fig. 4). In subsequent studies in cardiac myo-
cytes, it was also shown that contraction induced the
translocation of CD36 from an endosomal depot to the
plasma membrane (277).
Since these initial studies, others have confirmed that
contractile activity increases fatty acid transport via the
translocation of CD36 in skeletal muscle (443). Contrac-
tion can also induce the translocation of FABPpm in skel-
etal muscle (164, 219), as can AICAR-induced AMPK ac-
tivation in the heart (73). In addition, studies in cell lines
have confirmed, using cell surface labeling techniques,
that CD36 translocation is a rapid and reversible process
(118, 325, 460). Recently, we have also found that muscle
contraction increases the content of FATP1 and FATP4 at
the plasma membrane, while plasmalemmal FATP6 is not
altered (219). Nevertheless, CD36 is fundamental to facil-
itating the increase in fatty acid transport, since the con-
traction- or oligomycin-induced increase in fatty acid
transport rate is completely blunted in skeletal muscle
(44, 199, 219) and cardiac myocytes (153) by SSO and by
sulfo-N-succinimidylpalmitate (SSP), another specific in-
hibitor of CD36. Moreover, contraction-induced fatty acid
transport is lost in cardiac myocytes from CD36 knockout
mice (153) and is only minimally increased by the con-
traction mimetic agent caffeine in muscles of CD36
knockout mice (J. Lally and A. Bonen, unpublished data).
These latter studies on CD36 knockout mice have also
revealed that the reactive fatty acid esters (SSO, SSP) do
not exert nonspecific inhibitory effects on other fatty acid
transporters or on protein-independent fatty acid uptake.
The portion of CD36 that is stored in intracellular
compartments is estimated to be 50% both in skeletal
muscle (44) and heart (281). This intracellular CD36
depot was found to be enriched within subcellular frac-
tions containing GLUT4 and the transferrin receptor, an
endosomal protein (44). Hence, just like GLUT4, CD36
appears to recycle between endosomes and the sarco-
lemma. However, one report failed to observe an intra-
cellular CD36 depot in human muscle (464). This ob-
servation appears to be anomalous, as it is not sup-
ported by another similar microscopic study in human
muscle (236) or in the many subcellular fractionation
studies in humans (18, 48) and animals (71, 73–76, 164,
219, 272, 273, 277, 278, 282).
To morphologically characterize CD36 translocation
without using cell-disrupting procedures, Chinese ham-
ster ovary (CHO) cells stably expressing CD36 were cre-
ated (460). Immunofluorescence microscopy revealed
FIG. 3. Acute regulation of fatty acid uptake involves the cellular
redistribution of CD36. Left: fatty acid uptake into giant sarcolemmal
vesicles at selected time points during muscle contraction. Rat hindlimb
skeletal muscles were electrically stimulated via the sciatic nerve to
contract for 1, 5, and 30 min. Thereafter, muscle recovered from con-
traction for 20 and 45 min. At each time point, giant sarcolemmal
vesicles were prepared and fatty acid uptake determined. Right: amount
of sarcolemmal CD36 determined by Western blotting in resting muscle,
after 30 min of muscle contraction, and after 45 min recovery. [Data
from Bonen et al. (44).]
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CD36 to be located both intracellularly and at the plasma
membrane in a punctuate pattern. Upon treatment of
these cells with various metabolic stimuli, the punctuate
staining of CD36 at the plasma membrane increased by
1.7-fold, indicating the existence of specialized plasmale-
mmal regions involved in clustering of already present
and newly translocated CD36 (460, 461). Whether these
CD36 docking regions represent caveoli is uncertain,
given the conflicting evidence on the role of caveolins in
fatty acid transport (see sect. IIID).
Taken together, there is considerable evidence that
CD36 is present within an endosomal compartment in
muscle and heart. Whether GLUT4 and CD36 are
present within the same (presumably) endosomal com-
partment, or are stored in different subcompartments
within the endosomes, awaits further study. Unexpect-
edly, CD36 has also been located at the mitochondria
where it appears to contribute to regulating fatty acid
oxidation (see sect. IVC). Because the mitochondria are
not integrated with the recycling compartments encom-
passing the endosomes, it is very unlikely that mito-
chondria present a CD36 storage site for translocation
to the cell surface. As yet, little is known about the
dynamic distribution of other fatty acid transporters
between intracellular stores and the plasma membrane.
2. Endocrine-mediated and pharmacologically induced
regulation of fatty acid transport and transporters
It is well known that the uptake of glucose for cellu-
lar energy metabolism is regulated by the reversible trans-
location of the glucose transporter GLUT4 from endoso-
mal compartments to the sarcolemma in muscle and
heart, not only by changes in contraction, but also by
insulin and selected pharmacological agents (oligomycin,
AICAR, vanadate, arsenite) (24, 265, 267, 277, 282, 440).
Recent work in our group and by others has shown that
insulin and leptin, as well as the pharmacological agents
oligomycin, AICAR, and dipyridamole, induce the trans-
location of CD36 in skeletal muscle (164, 278, 305) and
heart (73, 153, 274, 281, 305, 324). Insulin has also been
reported to induce FATP1 translocation in adipocytes
(399), but this insulin-induced FATP1 translocation in
adipocytes was not observed in another study (346), or in
the heart (73, 152). Insulin also failed to induce the trans-
FIG. 4. Similarity between the regulation of cellular uptake of fatty acids and glucose. The uptake of both fatty acids and glucose by cardiac
and skeletal muscle is increased after translocation of specific transporter proteins (shown for CD36 and GLUT4, respectively) to the sarcolemma
in response to stimulation with insulin or during increased contractile activity. CD36 and GLUT4 may be mobilized from different stores within the
endosomal compartment. Note that, for clarity, the involvement of GLUT1 in glucose uptake and the recycling of other fatty acid transporters
(FABPpm and FATPs) are not shown, while recently it has been observed that they can also be induced to translocate, at least in skeletal muscle
(219). FA, (long-chain) fatty acid.
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location of FABPpm in heart (73). However, in skeletal
muscle, we (219) and others (479) have shown that insulin
does induce the translocation of FATP1 (219, 479), as well
as FABPpm (164, 219) and FATP4 (219), but not FATP6
(219). These studies indicate that the regulation of trans-
location of FABPpm and selected members of the FATP
family, but not CD36, appears to be tissue specific.
The recent observation that insulin-stimulated CD36
translocation and fatty acid uptake are additive to con-
traction-stimulated CD36 translocation and fatty acid
uptake (219, 278), just as has been observed for GLUT4
translocation and glucose transport (264), strongly sug-
gests that there are insulin- and contraction-responsive
intracellular subcompartments within the recycling endo-
somes dedicated to CD36 storage, as has previously been
shown for skeletal muscle GLUT4 (264). In contrast, the
insulin- and contraction-induced increases in plasmale-
mmal FABPpm, FATP1, and FATP4 are not additive (219),
suggesting that unlike CD36, there are no distinct insulin-
and contraction-responsive endosomal subcompartments
for these transporters.
B. Posttranslational Modification of Fatty
Acid Transporters
Subcellular translocation of fatty transporters has
been shown to rapidly upregulate fatty acid uptake into
(at least) heart and skeletal muscle (see sect. IVA). Addi-
tionally, other posttranslational mechanisms exist that
could provide a further level of short-term regulation of
fatty acid fluxes. These include palmitoylation, phosphor-
ylation, and ubiquitination of fatty acid transporters. All
three possible mechanisms are known to occur within a
time scale compatible with short-term regulation.
1. Palmitoylation of fatty acid transporters
Palmitoylation and myristoylation are the two major
types of covalent modification of proteins by fatty acids.
Whereas protein myristoylation is a cotranslational process
and a constitutive type of modification, protein palmitoyl-
ation is a short-term inducible event under hormonal regu-
lation. Protein palmitoylation involves a thioester linkage
catalyzed by specific protein fatty acyl-transferases and is
rapidly reversed by deacylases (25). Moreover, protein pal-
mitoylation is considered important in protein trafficking,
especially in targeting proteins to caveolae (149). As men-
tioned in section IIIB, CD36 possesses four palmitoylation
sites within the two small intracellularly located NH2- and
COOH-terminal domains (427) (Fig. 1B).
Interestingly, insulin, one of the major physiological
stimuli of fatty acid uptake, potently induces palmitoyl-
ation of CD36 in adipocytes (224). It has not yet been
investigated whether CD36 palmitoylation also occurs in
heart and muscle, and whether this palmitoylation can
alter the transport activity of CD36. It is also possible that
CD36 palmitoylation is not occurring independently of
CD36 translocation, but is one of the regulating steps in
insulin-induced CD36 translocation. The latter would be
in nice agreement with the proposed function of protein
palmitoylation, i.e., protein trafficking (149). Specifically,
CD36 palmitoylation could target CD36 to caveolae, al-
lowing the notion that these plasma membrane microdo-
mains could serve as a surface docking station for CD36
(see sect. IIID). Palmitoylation of the other fatty acid
transporters, i.e., FABPpm and the FATPs, has not been
reported.
2. Phosphorylation of fatty acid transporters
Protein phosphorylation is not only involved in rapid
alterations in enzymatic activity of, for instance, protein
kinases, but also in altering the intrinsic transport activity
of membrane transporters, such as the L-type calcium
channel (453). CD36 has been shown to possess at least
two phosphorylation sites, one being a consensus protein
kinase C (PKC) phosphorylation site at Thr-92 and one
protein kinase A (PKA) phosphorylation site at Ser-237,
which are both located within the extracellular loop (Fig.
1B). PKC-mediated CD36 phosphorylation has only been
studied in platelets and is involved in determining the
ligand specificity of CD36. In resting platelets, CD36 is
constitutively phosphorylated and binds mainly to colla-
gen. Platelet activation triggers the release of alkaline
phosphatase, which leads to dephosphorylation of CD36,
accompanied by a loss of collagen binding to CD36 and an
increase in thrombospondin binding (13). However, the
role of CD36-Thr-92 phosphorylation in fatty acid trans-
port has not yet been examined. In contrast, the Ser-237
site has been associated with the regulation of the trans-
port activity of CD36. In platelets, CD36-Ser-237 is phos-
phorylated by a cAMP-dependent ectokinase present at
the surface of platelets (177) when these platelets are
short-term incubated with cAMP and ATP. This CD36-Ser-
237 phosphorylation has been shown to modestly inhibit
fatty acid uptake by human platelets (151). However, the
functional significance of these findings is not yet clear
because it is not known whether there are physiological
conditions where cAMP and ATP are simultaneously
present at the outer surface of the platelets. Moreover,
whether ecto-PKA activity can regulate fatty acid uptake
in cells other than platelets is also not known. Finally, to
date, regulation of FABPpm and FATPs by phosphoryla-
tion has not been reported.
3. Ubiquitination of fatty acid transporters
Covalent linkage of proteins to ubiquitin, a 76-amino
acid peptide, is a regulatory posttranslational modifica-
tion enabling rapid degradation of these proteins. Lysine
residues at proteins to be degraded are conjugated to the
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COOH terminus of ubiquitin by the subsequent action of
ubiquitin-activating enzymes, ubiquitin-conjugating en-
zymes, and ubiquitin-protein ligases, after which the pro-
tein is targeted for degradation by the proteasome (83).
CD36 contains two lysine residues (Lys-469 and Lys-472)
within the small intracellular COOH-terminal domain that
appear to be major ubiquitination sites. CD36 ubiquitina-
tion is under hormonal and nutritional control because
treatment of C2C12 muscle cells for 30 min with insulin or
fatty acids has been found to inhibit or stimulate ubiquiti-
nation of CD36, and thereby prevent or accelerate its
degradation, respectively (388). These changes were par-
alleled by similar changes in fatty acid uptake. Combined
with the effects of insulin on CD36 subcellular localiza-
tion (see sect. IVA), it appears that insulin treatment of
myocytes increases sarcolemmal CD36 levels at two dif-
ferent posttranslational mechanisms, i.e., via induction of
CD36 translocation to the sarcolemma, and via protection
of sarcolemmal CD36 from degradation. Ubiquitination of
FABPpm and FATPs has not yet been reported.
C. Functioning of Fatty Acid Transporters in
Mitochondrial Fatty Acid Utilization
The idea that the rate of fatty acid oxidation by
muscle tissues is dictated by the rate of delivery of fatty
acids (concentration  blood flow) (155) is undergoing a
reassessment. As outlined above, this reevaluation is
based on recent experiments showing that fatty acid up-
take is regulated at the plasma membrane by the presence
of one or more fatty acid transporters. Interestingly, sev-
eral fatty acid transporters are also present at the mito-
chondria where they may contribute to regulating fatty
acid oxidation in concert with carnitine-palmitoyltrans-
ferase (CPT)-I.
1. Fatty acid oxidation
After entering muscle cells, a portion of the fatty
acids are activated by acyl-CoAs to long-chain fatty acyl-
CoAs in preparation for their import into mitochondria,
where they are oxidized to provide ATP for many cellular
processes. The CPT system is critically involved in the
movement of these fatty acyl-CoAs across the mitochon-
drial membranes. CPT-I catalyzes the transesterification
of fatty acyl-CoA to acyl-L-carnitine. The acyl-L-carnitine
can then be translocated to the inner mitochondrial mem-
brane by carnitine:acyl-L-carnitine translocase (CACT),
and finally acyl-CoA is regenerated from acyl-L-carnitine
by the latent CPT-II within the mitochondrial matrix
(240). However, while CPT-I activity is allosterically in-
hibited by malonyl-CoA (for review, see Refs. 296, 400),
the reduction in this malonyl-CoA, and changes in some
other regulators, cannot fully account for the CPT-I-me-
diated increase in fatty acid oxidation that occurs during
exercise (31, 317, 318, 356, 402). Thus other processes
must also be involved in upregulating fatty acid oxidation
in muscle tissues during exercise.
Since it is known that some transport proteins, such
as monocarboxylate transporters-1 and -2 (MCT-1 and -2)
that transport lactate and pyruvate (21, 481), as well as
mAspAT (69), a protein identical to FABPpm (26, 69, 217,
419, 485), are present at both the plasma membrane (45,
213, 286) and the mitochondrion (21, 26, 69, 217, 419, 481,
485), it has been suggested that fatty acid transport pro-
teins could also be present in mitochondria, where they
could possibly be involved in facilitating the movement of
fatty acids into the mitochondria.
2. Mitochondrial FABPpm
As noted above, FABPpm and mAspAT are identical
proteins (see sect. IIIA). Transfecting 3T3 fibroblasts (217)
or rat skeletal muscle (85, 200) with mAspAT cDNA in-
creased the content of plasmalemmal FABPpm and the
rate of fatty acid transport into 3T3 fibroblasts (217) and
skeletal muscle (85, 200). Concurrently, mitochondrial
FABPpm was also increased. However, this failed to alter
fatty acid oxidation in isolated mitochondria (200). In-
stead, mAspAT activity increased in proportion to its
mitochondrial overexpression (r  0.75) (200). Thus it
appears that FABPpm/mAspAT has two distinct functions
depending on its subcellular location: 1) at the plasma
membrane FABPpm contributes to fatty acid transport
across the plasma membrane, but 2) at the mitochondrion
mAspAT is involved in NADH transport across mitochon-
drial membranes (200).
3. Mitochondrial CD36 and FATP1
Studies in rat (64, 197, 200, 379, 481) and human
muscle (30, 198, 200, 203, 372) have shown that CD36 (30,
64, 197, 198, 200, 203, 372, 481) and FATP1 (379) are
present at both the plasma membrane and the mitochon-
drion. In addition, in skeletal muscle, CPT-I coimmuno-
precipitated with CD36 (64, 372, 379) and FATP1 (379).
Thus it appears that CD36 and CPT-I, and FATP1 and
CPT-I, could be involved in regulating mitochondrial fatty
acid oxidation. Evidence for this was reported in L6E9
myotubes in which overexpression of mitochondrial
CD36 or FATP1 increased fatty acid oxidation (379).
Similar studies have yet to be performed in mamma-
lian muscle. Nevertheless, strong support for a role of
CD36 in skeletal muscle mitochondrial fatty acid oxida-
tion has been shown in a number of studies. For example,
there is a high correlation between the rate of palmitate
oxidation in isolated mitochondria and the combined ef-
fects of mitochondrial CPT-I activity and CD36 content
(i.e., multiple regression, R  0.90) (30). Further support
came from studies in which rat muscles were induced to
contract by electrical stimulation (30 min) (64) or by
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exercise (2 h bicycle ergometry) (198). Mitochondria iso-
lated from these muscles showed an increase in the con-
tent of CD36 (64, 198), which correlated with an increased
rate of mitochondrial fatty acid oxidation (r  0.63) in
human muscle (198). These data suggest that CD36 trans-
locates from an as yet unidentified CD36 storage com-
partment to the mitochondria. It remains to be deter-
mined whether the recycling endosomes, the intracel-
lular storage pool for sarcolemmal CD36 (see sect. IVA),
might also provide a storage compartment for mito-
chondrial CD36.
Further human studies showed that there was a good
correlation between mitochondrial CD36 and mitochon-
drial fatty acid oxidation in lean and obese women (r 
0.67), independent of body mass index (BMI) (203). In-
creasing skeletal muscle CD36 protein expression, either
by chronic muscle stimulation in rats (7 days) (64) or with
a program of weight loss and exercise training in humans
(372), concomitantly increased fatty acid oxidation and
mitochondrial CD36. Moreover, the increased rate of
whole body fatty acid oxidation was correlated with an
increase in the CD36 associated with CPT-I (r  0.93), but
not with CPT-I alone (r  0.16) (372). Further support for
the involvement of CD36 with regulating mitochondrial
fatty acid oxidation came from studies with SSO, a spe-
cific blocker of plasmalemmal CD36 (153, 334) (see sect.
IVA1). This CD36 inhibitor reduced fatty acid oxidation by
80% in mitochondria obtained from both resting and
exercised skeletal muscle (30, 64, 198), although more
recent work has found that SSO is not CD36 specific in
mitochondria (199, 248). Because of this, the contribution
of CD36 in the regulation of mitochondrial fatty acid
oxidation has been questioned (248). In contrast, we (199)
and others (379) do observe a role for CD36 in mitochon-
drial fatty acid oxidation. Specifically, 1) in CD36 null
mice there is a reduced capacity for mitochondrial fatty
acid oxidation in resting muscle and a sharply diminished
ability to increase mitochondrial fatty acid oxidation in
response to muscle contraction (199), 2) overexpressing
mitochondrial CD36 in L6E9 myotubes increased the
rates of fatty acid oxidation (379), and 3) mitochondrial
fatty acid oxidation and mitochondrial CD36, but not
CPT-I, are increased in muscle of obese Zucker rats (199).
Taken together, there is strong evidence to suggest that
CD36 and possibly FATP1 are involved, along with CPT-I,
in regulating mitochondrial fatty acid oxidation.
It is questionable whether in mammalian muscle FATP1
is as effective as CD36 in regulating fatty acid metabolism.
Presently, it is not known whether FATP1, like CD36, is
induced to translocate to the mitochondrion, when muscle
metabolic demand is increased. Moreover, recent work has
shown that under basal conditions FATP1 has 1) a consid-
erably lower fatty acid transport capacity and 2) a much
lower stimulatory effect on fatty acid oxidation than CD36 in
intact muscle (315). This may suggest that CD36 is likely
more important than FATP1 in contributing to the regulation
of mitochondrial fatty acid oxidation.
The mechanism(s) by which CD36 in combination
with CPT-I contributes to the regulation of mitochondrial
fatty acid oxidation is still unclear. We speculate that
mitochondrial CD36 could perform a function that mir-
rors that of plasmalemmal CD36. Namely, upon cellular
fatty acid uptake, plasmalemmal CD36 donates the fatty
acids to FABPc, the vehicle for cytoplasmic fatty acid
transport to, among others, the mitochondria (142). This
transfer of fatty acids most likely involves a direct inter-
action between CD36 and FABPc (396). Conversely, mi-
tochondrial CD36 could facilitate the unloading of FABPc
by accepting the fatty acids for transfer to ACS for acti-
vation.
Given that CD36 can be induced to translocate to
both the plasma membrane and to the mitochondria, it
appears that the rate of fatty acid oxidation is not solely
dependent on the rate of fatty acid delivery (concentra-
tion  blood flow) to the muscle tissues, as has long been
thought, particularly during exercise (155). We are now
proposing an alternate model for upregulating skeletal
muscle fatty acid oxidation, one that involves the muscle
contraction-induced subcellular trafficking of CD36. Spe-
cifically, the proposed model (201) is a highly regulated
and coordinated two-site system that responds rapidly to
the muscles’ metabolic needs to increase fatty acid oxi-
dation during exercise. In this model muscle contraction
or exercise 1) induces the translocation of CD36 to the
plasma membrane, thereby increasing fatty acid uptake
into the muscle cell (see sect. IVA), and 2) induces the
translocation of CD36 to the mitochondrion, where it
interacts with CPT-I to increase fatty acid uptake into the
mitochondrial matrix to be oxidized (see above). This
scheme does not imply that 1) other fatty acid transport-
ers are not involved and 2) an increased delivery of fatty
acids via the circulation is unimportant. Rather, this pro-
posed model provides a means whereby intracellular sig-
nals initiated by muscle contraction can very rapidly (min-
utes) to regulate the increase in energy supply into the
tissue towards the site of ATP synthesis so as to meet the
increased metabolic demands.
D. Coordinated Functioning of Fatty
Acid Transporters
It is conceivable that rapid fluctuations in metabolic
needs of the heart and skeletal muscle require a distinct
mechanism for fatty acid uptake, one that is different
from the system that supports fatty acid entry, or release,
from adipose cells. The possibility that selected fatty acid
transporter proteins might function in a coordinated man-
ner was suggested in the previous decade (142, 143, 286),
and there is some experimental support for this idea.
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Studies in skeletal muscle and cardiac myocytes have
shown that fatty acid uptake was blocked independently,
by inhibitors of CD36 and FABPpm, but their effects were
not additive (286), suggesting that these two proteins
interact with each other to take up fatty acids. Support for
this has also been found in other studies. For example, the
insulin- and AICAR-stimulated increases in fatty acid up-
take did not correlate well with only plasmalemmal CD36
or with only plasmalemmal FABPpm. Instead, the rate of
fatty acid uptake was linearly related to the sum of plas-
malemmal CD36 and plasmalemmal FABPpm (75). A sim-
ilar observation occurred in heart and muscle of type 1
diabetic rats (272). Thus there is enticing evidence to
suggest that FABPpm and CD36 may interact with each
other. In addition, CD36 and caveolin-1 might interact
with each other (see sect. IIID). Whether any of these
latter proteins also interacts with FATPs is unknown,
although this may occur as CD36 and FATP6 colocalize in
the heart (139). As noted in section IVB, a concerted action
among membrane fatty acid transporters, and other pro-
teins such as cytoplasmic FABP (143, 396) and ACS-1
(279, 346), may allow a fine-tuning of fatty acid transport
so as to have this substrate readily available for intracel-
lular utilization.
E. Do Fatty Acid Transporters Channel Fatty
Acids to a Particular Metabolic Fate?
It has been suggested, based on the overexpression
of fatty acid transporters in different cell lines, that spe-
cific transport proteins interact with specific intracellular
proteins to channel fatty acids to different metabolic fates
within the cell (20, 136, 176, 346, 487). Some evidence was
recently shown for this in 3T3-L1 adipocytes, in which
FATP1 and ACS1 coimmunoprecipitate (346). Overex-
pression of ACS1 increased the rate of fatty acid trans-
port, leading to the conclusion that constitutive interac-
tion between FATP1 and ACS1 contributes to the efficient
cellular uptake of fatty acids in adipocytes through vec-
torial acylation. This led to the suggestion that fatty acid
esterification might be required to stimulate fatty acid
uptake into adipocytes (346). Others have shown a role
for ACS1, -4, and -6 in contributing to fatty acid transport
(432). However, as reviewed above, fatty acid transport is
not dependent on activation by ACS1, but, in vivo, these
two processes (fatty acid transport and activation) are
likely complementary (see sect. IIIC).
While fatty acid channeling via different fatty acid
transporters to different intracellular fates is an attractive
hypothesis to account for the large number of fatty acid
transporters expressed in a number of tissues, supporting
evidence is only available from studies in vitro, in selected
cell lines in which normal physiological regulation is
largely absent. Moreover, unlike skeletal muscle and the
heart, very rapid adjustments in fatty acid provision are
not required in quiescent cells with a low metabolic rate.
In vivo, fatty acid channeling to a particular meta-
bolic fate via specific fatty acid transporters would not
seem to hold, particularly in metabolically dynamic tis-
sues such as heart and skeletal muscle. Such a scheme
ignores the important role of physiological signals such as
hormones (insulin) and muscle contraction. Each of these
stimuli can induce the translocation of FABPpm, CD36,
FATP1, and FATP4 (219), thereby increasing the rate of
fatty acid uptake. Following their uptake, the fate of these
transported fatty acids is most likely regulated by insulin-
specific and contraction-specific intracellular signals that
direct fatty acids to esterification or oxidation, respec-
tively, consistent with the metabolic needs of the tissue.
Specifically, the contraction-induced increases in the sar-
colemmal pool of CD36 (see sect. IVA) are linked with
enhanced fatty acid oxidation (44, 213, 277, 290, 305), and
the insulin-induced increases in sarcolemmal CD36 with
enhanced fatty acid esterification (278, 281). Observations
in CD36 knockout animals further underscore this notion,
as in AICAR-stimulated muscles CD36 ablation selectively
impairs fatty acid oxidation while in insulin-stimulated
muscles CD36 ablation results in a selective reduction of
fatty acid esterification (42). In line with this, pharmaco-
logical blockade of CD36 in cardiomyocytes (287) or ab-
lation of CD36 in muscle (42) in the absence of metabolic
stimuli reduces basal rates of both muscle fatty acid
uptake, esterification, and oxidation to the same extent,
indicating that sarcolemmal CD36 does not channel fatty
acids specifically into oxidation or esterification. To-
gether, these observations strongly indicate that the met-
abolic machinery rather than sarcolemmal CD36 per se
determines the ultimate intracellular metabolic fate of
incoming fatty acids.
The metabolic fate of fatty acids that have been
transported into heart and muscle is dictated by intracel-
lular signals, fashioned by the energetic demands, i.e.,
contractile activity (112, 277, 385, 386) and/or the endo-
crine milieu (e.g., insulin and leptin; Refs. 115, 278, 281,
309, 310, 405). For contractile activity and leptin, the
intracellular signal is AMP-kinase activation, which exerts
an inhibitory phosphorylation of acetyl-CoA carboxylase,
thereby lowering the intracellular malonyl-CoA concen-
tration. Consequently, CPT-I becomes deinhibited, allow-
ing the mitochondrial -oxidation rate to increase (270,
400). With respect to insulin, this anabolic hormone has
been found, at least in adipocytes, to acutely upregulate the
activity of glycerol-3-phosphate acyltransferase (GPAT; the
rate-limiting enzyme in triacylglycerol synthesis) (462),
likely through phosphorylation within a consensus motif for
casein kinase-2 (56), a known protein kinase target of insulin
signaling (247). Whether recruitment of other fatty acid
transporters and/or members of the ACS family respond
differentially to these stimuli to act in concert with CD36
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possibly to channel fatty acids to different fates is not
known.
In summary, translocation of fatty acid transporters
provides a very rapid, localized regulation of lipid metab-
olism at the level of the plasma membrane. In contracting
muscles we propose that this may be accomplished by
coordinating fatty acid uptake and mitochondrial oxida-
tion via translocation of CD36 to these subcellular loca-
tions at the same time. Cofunctioning of fatty acid trans-
porters at the plasma membrane has been shown and may
also occur at other subcellular locations, such as mito-
chondria. Additional levels of regulation may exist, in-
cluding possibly ectophosphorylation of CD36 to diminish
fatty acid uptake, as has been shown in human platelets
(151), CD36 palmitoylation (427), and association with
specific membrane microdomains such as lipid rafts
(117). Channeling of fatty acids to a particular metabolic
fate within the muscle cells, in vivo, is likely directed by
intracellular metabolic signals generated by muscle con-
traction or the endocrine milieu, and may involve selec-
tive recruitment of one or more fatty acid transporters
and/or members of the ACS family depending on the
physiological signal (e.g., contraction or hormones).
V. SIGNALING AND TRAFFICKING EVENTS
REGULATING MEMBRANE
TRANSPORTER TRANSLOCATION
In the previous section it was outlined that fatty acid
uptake is regulated by a translocation of fatty acid trans-
porters from intracellular stores to the sarcolemma.
Hence, the sarcolemmal presence of these transporters is
not fixed, but can be altered dynamically in coordination
with the continuously changing metabolic demands of
heart and muscle.
CD36 and FABPpm are examples of proteins, with cell
surface-related functions (receptors and transporters), that
recycle to and from the sarcolemma. Even under basal,
nonstimulated conditions (low metabolic demand) and con-
sequently a low fatty acid uptake rate, there is no static
distribution of fatty acid transporters, but instead a contin-
uous recycling between the endosomal compartment and
the sarcolemma in such a manner that the combined rates of
endocytosis and exocytosis result in a low basal surface
localization (for review, see Ref. 276). Theoretically, in-
creased exocytosis or decreased endocytosis could result in
net transporter relocation. From extensive research on
GLUT4 translocation in adipocytes, it would seem that a net
transporter redistribution to the sarcolemma upon exposure
of cardiac tissue or cells to a given stimulus is caused by an
increase in the rate of exocytosis without any change in the
rate of endocytosis (which is regarded as noninducible in
this translocation model). This is currently the most favored
view of the regulation of transporter translocation (207, 365,
428), although a decreased endocytosis may also contribute
to net GLUT4 translocation (263). Nevertheless, in general,
endocytosis is regarded as an unregulatable (housekeeping)
trafficking event, while in contrast exocytosis is highly in-
ducible.
Conceptually, the events regulating the net translo-
cation of a given recycling protein, i.e., CD36, can be
subdivided into 1) stimulus-induced signaling and 2) in-
duction of trafficking processes, presumably acting on
acceleration of exocytosis (Fig. 5). The signaling events
can be induced by various mechanical, hormonal, or phar-
macological stimuli (see sect. IVA). Each of these stimuli
will induce the activation of key/master protein kinases,
which initiate a pleiotrophy of signaling cascades, allow-
ing cells to perform the full range of responses needed to
adequately respond to changing metabolic conditions.
With respect to regulation of subcellular transporter dis-
tribution, one (or more) of these stimulus-induced signal-
ing cascades will activate the vesicular trafficking ma-
chinery, thereby modulating the continuous recycling of
membrane receptors and transporters to achieve a net
translocation of these proteins.
A. Signaling Pathways
Insulin and contraction are the main physiological
stimuli able to induce fatty acid uptake through translo-
cation of CD36 and/or FABPpm, as well as FATP1 and -4.
Both stimuli activate distinct signaling cascades. Whereas
the insulin-signaling cascade starts from the extracellular
leaflet of the sarcolemma, the origin of the contraction
signaling cascade is intracellular.
1. Insulin signaling
The components involved in the postreceptor insulin
signaling pathway, that induce GLUT4 translocation to
stimulate glucose transport, are well known and have
been the topic of extensive research during the last two
decades. This signaling pathway may also be involved in
insulin-stimulated fatty acid transporter translocation.
Therefore, we briefly review below the sequence of sig-
naling events involved in insulin-stimulated GLUT4 trans-
location, as a framework for examining insulin-stimulated
fatty acid transporter (particularly CD36) translocation.
A) INSULIN SIGNALING PATHWAYS IN GLUT4 TRANSLOCATION. The
binding of insulin to the -subunit of the insulin receptor
induces a conformational change throughout the whole
protein, resulting in the autophosphorylation of the recep-
tor -subunit at tyrosine residues, thereby providing
docking sites for phosphotyrosine-binding (PTB) domain
containing proteins, most critically the insulin receptor
substrates (IRS), of which IRS-1 is the key player in
muscle and the heart. In addition, members of the class 1
phosphatidylinositol-3 kinases (PI3Ks) are activated by
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the binding of its p85 regulatory subunit to the phosphor-
ylated IRS-1, thereby recruiting PI3K to the plasma mem-
brane. PI3Ks form a family of enzymes phosphorylating
the D-3 position on the inositol ring in phosphoinositides,
and class 1 PI3Ks specifically convert phosphatidylino-
sitol 4,5-bisphosphate into phosphatidylinositol 3,4,5-
trisphosphate (PIP3) for downstream activation of in-
sulin signaling. Investigations on the involvement of
FIG. 5. Trafficking pathways involved in CD36 recycling. The transition of CD36 from the endosomal storage compartment to the plasma
membrane, and vice versa, is regulated by several protein families with different functions. 1, Bottom inset: adaptor proteins and Rab-GTPases
regulate the binding of coat proteins to areas enriched in CD36. The formation of coat complexes leads to the generation of a CD36 transport vesicle
which is released to the cytoplasm by scission proteins. After budding of the vesicle, the adaptor and coat proteins again detach. 2: Upon binding
of a motor protein, the transport vesicle is moved along cytoskeleton filaments to its designated target membrane. Also this process is initiated by
Rab-GTPases. 3, Top inset: tethering proteins trap the transport vesicle below the cell surface. The interaction of a specific subset of vesicle-
associated SNAREs (v-SNAREs) and target-membrane associated SNAREs (t-SNAREs) brings the vesicle to such a close proximity to the plasma
membrane that the water barrier can be overridden and fusion of the two membranes can occur. After fusion, the SNARE complex disintegrates.
4–6: The transport of CD36 from the plasma membrane to the endosomal compartment proceeds analogous to steps 1–3.
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PI3K in GLUT4 translocation have been greatly facili-
tated by the use of pharmacological inhibitors, such as
wortmannin and LY294002. Numerous publications re-
port that both inhibitors largely abolish insulin-induced
GLUT4 translocation and glucose uptake (for review,
see Ref. 381).
The lipid signaling intermediate PIP3 is not only reg-
ulated by its PI3K-mediated formation, but also by its
degradation rate by inositol phosphatases, namely, SH2
domain-containing 5-inositol phosphatase (SHIP)-2, and
the tumor suppressor gene product PTEN (phosphatase
and tensin homolog deleted on chromosome 10), dephos-
phorylating PIP3 at the 3 position. Hence, these inositol
phosphatases are involved in the regulation of GLUT4
translocation (368, 426). The formation of PIP3 at the
plasma membrane directly drives the activation of a num-
ber of different protein kinases with lipid binding do-
mains, of which three have now been recognized as es-
sential players in insulin-induced glucose uptake, namely,
Akt/protein kinase B (PKB), PKC-/, and 3-phosphoino-
sitide-dependent protein kinase-1 (PDK1). Binding of PIP3
induces a conformational change within these kinases
resulting in their autophosphorylation or plasma mem-
brane binding.
The importance of Akt, especially isoform 2, in the
regulation of glucose uptake has been revealed in Akt2
null mice (81, 137). The activation of Akt is complex in
that it requires dual phosphorylation at Ser-473 and Thr-
309 in addition to its PI3K-mediated recruitment to the
plasma membrane. The Thr-309 phosphorylation within
the activation loop is mediated by PDK1 (9), in which
involvement in cardiac insulin-stimulated glucose uptake
was subsequently demonstrated by the inability of cardiac
myocytes from muscle-specific PDK1 null mice to in-
crease glucose uptake upon insulin treatment (306).
In parallel to Akt2, PKC- is activated by PDK1, upon
unfolding of the pseudosubstrate domain and exposure of
the activation loop Thr-410 site (122). The involvement of
PKC-/ in insulin-induced GLUT4 translocation and glu-
cose uptake has been convincingly proven in muscle cell
lines expressing dominant-negative mutants (17). The si-
multaneous and combined activation of Akt2 and PKC-/
is necessary for insulin-induced GLUT4 translocation in
both heart (29) and skeletal muscle (122). Akt is known to
activate a great number of substrates involved in a pleio-
trophy of anabolic responses. Among these, the phos-
phorylation of an Akt substrate of 160 kDa (AS160) has
been found to be particularly important for GLUT4 trans-
location (367, 483). Insulin-stimulated phosphorylation of
AS160 (IR 3 IRS1-PI3K 3 Akt2 3 AS160) releases the
inhibition on vesicular GLUT4 movement to the plasma
membrane, as phosphorylated AS160 can no longer main-
tain rab proteins in a GDP-bound state. Although PKC-/
targets involved in insulin-induced GLUT4 translocation
have not been examined intensively, it appears that PKC-
/ binds to intracellular GLUT4 compartments upon in-
sulin stimulation and directly phosphorylates the GLUT4
compartment-associated vesicle-associated membrane
protein-2 (VAMP2) (52). Hence, Akt2-mediated AS160
phosphorylation, as well as PKC-/-mediated VAMP2
phosphorylation, are at the threshold between insulin-
induced signaling and trafficking events in the transloca-
tion of GLUT4 to the cell surface. Excellent, detailed
reviews discussing more fully the insulin-stimulated sig-
naling pathway involved in promoting GLUT4 transloca-
tion are available (29, 68).
B) INSULIN SIGNALING PATHWAYS IN FATTY ACID TRANSPORTER
TRANSLOCATION. Similarly to insulin-induced GLUT4 transloca-
tion, the insulin-induced translocation of fatty acid trans-
porters requires the activation of PI3K. Namely, inhibition of
this kinase by either wortmannin or LY294002 inhibited
fatty acid uptake and CD36 translocation in cardiac myo-
cytes (281) and skeletal muscle (278). However, it cannot
yet be deduced which class of PI3K contributes to insulin-
stimulated fatty acid uptake because wortmannin and
LY294002 potently inhibit most isoforms (381). Likely,
class II PI3Ks can be excluded because isoforms within
this class are relatively resistant towards both inhibitors
(108). Recent studies in L6 muscle cells and in primary
cardiac myocytes using pharmacological inhibitors have
found that downstream of PI3K, atypical PKC-, but not
PKB/Akt, mediates the effects of insulin on fatty acid
uptake (239) via translocation of CD36 (284). In contrast
to L6 muscle cells, it does appear, however, that Akt-2 is
required in mammalian muscle for insulin-induced fatty
acid transport and for the translocation of selected fatty
acid transporters. Specifically, we have found that insulin
1) failed to stimulate fatty acid and glucose transport in
skeletal muscle of Akt-2 null mice, and 2) failed to induce
the translocation of CD36 and FATP1, as well as GLUT4,
while the translocation of FABPpm and FATP4 was not
impaired (218). These observations indicate that insulin-
stimulated GLUT4 translocation and the insulin-stimu-
lated translocation of some fatty acid transporters (CD36
and FATP1) are similarly regulated via the PI3K-Akt2
signaling pathway. It is possible, however, via the use of
arsenite, to divorce the translocation of GLUT4 from that
of CD36 (282). Similarly, CD36 translocation could be
divorced from the translocation of FABPpm and of FATP4
in Akt-2 null mice (218). These observations indicate that
insulin signaling pathways for GLUT4 and selected fatty
acid transporters can at times diverge, either because
signals diverge at some point beyond Akt-2 or different
subcellular depots of fatty acid transporters are targeted.
2. Contraction signaling
The metabolic demands of muscle contraction favor
the activation of nutrient and stress sensing cascades.
Hence, an increase in contractile activity can result in a
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rapid rise in the concentration of a number of second
messengers in heart and muscle, such as AMP, cAMP,
Ca2, and reactive oxygen species (ROS). Together these
second messengers activate a complex network of signal-
ing events (353). Among all the protein kinases activated
by contraction [e.g., PKA, PKC- and -, extracellularly
regulated protein kinases (ERK)-1 and -2, mitogen-acti-
vated protein kinase (MAPK), and Ca2/calmodulin-de-
pendent protein kinases (CaMK)], the activation of AMP-
activated protein kinase (AMPK) is known to have a
variety of metabolic actions (275, 352), including the stim-
ulation of fatty acid oxidation via the phosphorylation and
inactivation of acyl-CoA carboxylase (ACC) and the con-
sequent reduction in malonyl-CoA which releases the in-
hibitory effects on CPT-I (270, 400). In line with this, we
have shown that AMPK plays a crucial role in the trans-
location of CD36 (73, 277), and that of FABPpm (73).
Importantly, some of the other mentioned contraction-
activated kinases are not involved in contraction-induced
fatty acid transport, including cAMP-activated PKA (289)
and conventional or novel PKCs (288).
Based on the central role of AMPK in contraction-
induced fatty acid transport, we will discuss which addi-
tional protein kinases could be involved in the AMPK
signaling pathway to induce fatty acid transporter trans-
location. This will necessarily be confined to CD36, as
similar details are currently not available for other fatty
acid transporters.
A) INVOLVEMENT OF AMPK IN CONTRACTION-INDUCED FATTY ACID
UPTAKE. AMPK is a heterotrimeric protein consisting of
catalytic (1, 2) and regulatory (1, 2, 	1, 	2a, 	2b, 	3)
subunits (168, 170). Both AMPK1 and AMPK2 are ex-
pressed in heart and skeletal muscle, of which AMPK2 is
the predominant subunit (401). Activation of the AMPK
complex occurs mainly via AMP by three independent
mechanisms: 1) promotion of phosphorylation of Thr-172
within the -subunit by upstream kinases, 2) allosteric
activation of the phosphorylated enzyme, and 3) inhibi-
tion of dephosphorylation of Thr-172 by protein phospha-
tases (171). Under conditions that favor a rapid increase
in intracellular AMP, such as during increased contractile
activity in muscle (477) or during a period of cardiac
ischemia (259), AMPK becomes activated, resulting in the
activation of catabolic pathways, such as the increased
oxidation of fatty acids (exercise) and glucose (ischemia),
and the deactivation of anabolic pathways, such as stor-
age of these substrates (169).
Evidence that AMPK is involved in contraction-induced
fatty acid transport comes from the observation that con-
traction-induced fatty acid uptake is not additive to that of
agents able to activate AMPK and increase fatty acid trans-
port. However, it must be recognized that some recent stud-
ies have begun to suggest that AMPK is not necessarily
essential for the regulation of fatty acid oxidation by AICAR
or muscle contraction (116, 357). Nevertheless, AMPK-acti-
vating agents, oligomycin (a mitochondrial F1F0-ATPase in-
hibitor) and AICAR (a cell-permeable adenosine analog,
which is converted intracellularly to ZMP, an AMP analog),
induce the translocation of CD36 (73, 277) and FABPpm (73)
to the sarcolemma. Because muscle contraction (44) and
these contraction-mimetic agents failed to stimulate fatty
acid transport, either into skeletal muscle or cardiac myo-
cytes (277) treated with the specific CD36 inhibitor SSO (44,
277), or in cardiac myocytes from CD36 null mice (153), it is
evident that AMPK-activated induction of CD36 transloca-
tion is largely, if not entirely, responsible for increasing fatty
acid transport. More direct evidence for the involvement of
AMPK in contraction-induced fatty acid transport was ob-
tained with cardiac myocytes from mice overexpressing an
AMPK2 kinase-dead subunit, since this dominant-negative
mutant resulted in a severely reduced activation of both
AMPK1 and AMPK2, and in a complete abolishment of
oligomycin- or AICAR-induced fatty acid uptake (152). Sim-
ilarly, oligomycin-induced fatty acid uptake was also com-
pletely lost in cardiac myocytes from AMPK2 knockout
mice, indicating that in the heart AMPK2, not AMPK1, is
responsible for contraction-induced fatty acid uptake (152).
In this respect, contraction-induced cardiac fatty acid up-
take closely resembled contraction-induced GLUT4 translo-
cation, which was also found to be entirely and selectively
dependent on AMPK2 activation in the heart (152).
Whether the translocation of CD36 and possibly
other fatty acid transporters in skeletal muscle is also
fully AMPK2 dependent is questionable. It is now known
that during muscle contraction the two -isoforms
(AMPK1 and AMPK2) can substitute for each other in
terms of activity, which may explain the normal glucose
uptake despite the lack of either AMPK1 or AMPK2 in
genetically altered mice (227). Thus the roles of AMPK1
or AMPK2 in promoting fatty acid transporter transloca-
tion and fatty acid uptake in skeletal muscle remain to be
determined.
B) CONTRACTION SIGNALING UPSTREAM OF AMPK. In the late
1980s, kinase activity towards AMPK-Thr-172 (referred to
as AMPKK) was detected as a distinct entity in a partial
purification of AMPK from rat liver (67). However, it
proved to be difficult in subsequent years to purify the
kinase-kinase to homogeneity. Fortunately, independent
research in yeast provided important clues in the identi-
fication of AMPKK. Namely, Snf1, the yeast homolog of
AMPK, is phosphorylated by three kinases (204), and
database searches revealed three closely related mamma-
lian kinases, LKB1, CaMKK, and CaMKK (166). LKB1
has a ubiquitous expression pattern in mammalian tis-
sues, whereas the expression of CaMKKs is restricted to
brain, and to a lesser extent to muscle tissues (11; and see
reviews in Refs. 167, 463). In vivo, LKB1 and CaMKK are
each regulated differently. In muscle tissue, CaMKK ac-
tivity is inducible, i.e., by an increase in intracellular Ca2
(179). In contrast, LKB1 is constitutively active (363), but
388 GLATZ, LUIKEN, AND BONEN
Physiol Rev • VOL 90 • JANUARY 2010 • www.prv.org
Downloaded from journals.physiology.org/journal/physrev at Universiteit Maastricht (137.120.149.252) on September 27, 2021.
it can only activate AMPK during conditions when intra-
cellular AMP is increased (e.g., exercise), as AMP binding
to AMPK induces a conformational change within the
AMPK complex so that Thr-172 becomes accessible to
phosphorylation by LKB1 (178). While LKB1 has been
shown to be involved in contraction-induced glucose up-
take in muscle (364), it is still controversial whether
CaMKK regulates contraction-stimulated glucose uptake
in muscle via AMPK activation (222, 223, 478).
Recently, cardiac myocytes from LKB1 null mice
were used to examine oligomycin- and AICAR-stimulated
fatty acid uptake (152). These studies demonstrated that
the stimulatory effects of each of these AMPK-activating
agents on fatty acid uptake and CD36 translocation were
lost, indicating that LKB1 is the primary AMPKK involved
in this metabolic action. Since AICAR and oligomycin
each stimulates fatty acid uptake in a nonadditive manner
to contraction (152, 277), the AICAR and oligomycin find-
ings can be extrapolated to contraction, namely, that an
LKB1-AMPK signaling axis is necessary for contraction-
induced fatty acid uptake via CD36 translocation. In skel-
etal muscle, the regulation of contraction-induced fatty
acid uptake may occur in part via Ca2-dependent activa-
tion of CaMKK and AMPK (343, 344), but whether these
signals induced the translocation of one or more fatty acid
transporters was not determined.
C) CONTRACTION SIGNALING DOWNSTREAM OF AMPK. To date,
close to 20 direct cellular targets of AMPK have been
identified (434). This number is expected to grow given
the critical role of AMPK in cellular energy homeostasis.
A consensus recognition motif has now been identified
around the site phosphorylated by AMPK (434). Proteins
with these motifs include selected transcription factors
and a few signaling proteins, as well as proteins involved
in fatty acid and glucose metabolism. One signaling pro-
tein in particular stands out, namely, AS160. It is strongly
implicated in insulin-induced GLUT4 translocation and is
likely also involved in insulin-induced fatty acid trans-
porter translocation, given that its upstream kinase Akt-2
is required for insulin-stimulated fatty acid transport and
fatty acid transporter translocation (CD36 and FATP4;
Ref. 218; see sect. VA1). Indeed, it is now firmly estab-
lished that in skeletal muscle AS160 is phosphorylated
in vivo both by insulin and by exercise, and in situ by
electrically induced muscle contraction as well as by
AICAR (68, 257), while AS160 phosphorylation is absent
in mice deficient in AMPK signaling (435). It now appears
that AS160 is a possible point of convergence for insulin-
and contraction-signaling pathways from where traffick-
ing processes are activated for simultaneous GLUT4 and
CD36 translocation.
There are also several protein kinases, most notably
ERK-1/-2 and PKC-, reported to operate in contraction-
stimulated glucose uptake in skeletal muscle (79). Inter-
estingly, ERK has also been proposed to be involved in
contraction-induced CD36 and fatty acid uptake in skele-
tal muscle, based on the ability of the ERK inhibitor
PD98059 to inhibit these events (345, 443). More recent
work indicated that contraction-induced fatty acid uptake
may occur in part via Ca2-independent activation of
ERK1/2 (343). Another protein kinase recently identified
to be necessary for contraction-induced GLUT4 translo-
cation is protein kinase D-1 (PKD1), which is activated
independently from AMPK (288). Whether PKD1 has a
role in contraction-induced fatty acid transporter translo-
cation has not yet been assessed.
B. Trafficking Pathways
A sequence of trafficking events resulting in translo-
cation of transporter proteins is initiated once the insulin-
or contraction-induced signaling cascades have been
completed. The cellular machinery responsible for migra-
tion of cargo from one compartment to the other, and vice
versa, is referred to as the trafficking machinery. Regula-
tion of this transport needs to be unidirectional and ex-
tremely specific to ensure that vesicles containing cargo
(e.g., CD36 and/or GLUT4) destined for the plasma mem-
brane do not fuse randomly with membranes from other
organelles (99). To provide the unidirectionality of intra-
cellular transport, and the proper sorting mechanisms,
each mammalian cell type contains a specific set of traf-
ficking proteins, dedicated to adequately meet this spe-
cific function. Derived from research with nerve cells for
the secretion of neurotransmitters and adipocytes for the
translocation of GLUT4 (99), the list of proteins that make
up the cellular trafficking machinery includes the follow-
ing (Fig. 5).
1. SNARE proteins
Soluble N-ethylmaleimide attachment protein recep-
tor (SNARE) proteins are responsible for safeguarding
the specificity of the transport of intracellular membrane
vesicles according to the principles of the so-called
SNARE hypothesis (99). This hypothesis postulates that
in vesicular trafficking events a unique vesicle-associated
protein (v-SNARE) specifically recognizes and interacts
with a cognate t-SNARE protein localized at the target
membrane. This specific interaction results in the forma-
tion of a SNARE-pin complex necessary for the fusion of
vesicles with their target compartments.
2. Rab proteins
Ras-related Rab GTP-binding proteins bind and hy-
drolyze GTP. In their cycling between GTP-bound (active)
and GDP-bound (inactive) conformations, these proteins
act as molecular switches in vesicular trafficking (102).
Although Rabs have not been detected in the SNARE
FATTY ACID TRANSPORTERS AND LIPID METABOLISM 389
Physiol Rev • VOL 90 • JANUARY 2010 • www.prv.org
Downloaded from journals.physiology.org/journal/physrev at Universiteit Maastricht (137.120.149.252) on September 27, 2021.
complex, they are probably required for the assembly of
this complex, as has been shown in yeast (390). Members
of the Rab family are associated with distinct intracellular
compartments involved in endocytic and exocytic pro-
cesses, indicating that the individual Rab proteins have
specialized transport functions.
3. Coat/scaffolding proteins
Coat proteins are required for the generation of highly
curved membranes and the assembly of accessory proteins
into a “vesicle fission complex.” Subcellular trafficking ves-
icles possess characteristic proteinaceous coat structures
allowing their classification accordingly into 1) clathrin-
coated vesicles, 2) COP-coated vesicles, and 3) caveolin-
coated vesicles (caveolae). It is disputed whether these dif-
ferent classes indeed perform different trafficking actions
(297).
4. Other proteins
Other proteins involved include motor proteins (dy-
namins), adaptor proteins for complex formation and cargo
assembly (-arrestin), phosphatidylinositol kinases for gen-
eration of bilayer destabilizing phospholipids necessary for
vesicle budding, GTPases involved in vesicle fission (ARFs),
uncoating proteins (auxillin), filamentous proteins providing
the “highway” along which the substrate transporter-con-
taining vesicle travels to the cell surface (297).
Below we summarize the as yet limited information
currently available on the involvement of some of these
proteins in the regulation of fatty acid transporter re-
cycling. These findings will be discussed against the
background of a steadily growing list of proteins found
to be involved in insulin-stimulated GLUT4 transloca-
tion.
A) SNARE PROTEINS. In muscle tissues, insulin-induced
GLUT4 translocation is the most intensively studied process
in relation to SNARE proteins. In these tissues, vesicle-
associated membrane protein-2 (VAMP-2) appeared to
be the v-SNARE involved, and syntaxin-4 the cognate
t-SNARE, which operates in conjunction with the
SNARE-related protein SNAP-23 (for review, see Refs.
127, 397). SiRNA experiments have indicated that
GLUT4 exocytosis induced by hyperosmolarity (a PI3K-
independent stimulus) is not mediated by VAMP-2, but
by VAMP-7, and that VAMP-8 is responsible for GLUT4
endocytosis (475). It is not yet known whether these
same SNARE proteins are involved in fatty acid trans-
porter translocation, and whether insulin-induced
CD36 translocation requires identical or different
SNAREs compared with contraction-induced transloca-
tion of CD36 or FABPpm. However, the involvement of
PKC- in insulin-stimulated fatty acid uptake (possibly
through CD36 translocation) might suggest that
VAMP-2 is involved in insulin-induced CD36 transloca-
tion similar to its involvement in insulin-induced
GLUT4 translocation. Namely, VAMP-2 is recognized as
a direct phosphorylation target of PKC- (see sect.
VA1).
B) RAB PROTEINS. In muscle cells and adipocytes, at
least three species of Rab proteins were found to be
involved in the regulation of GLUT4 translocation: Rab 4
and Rab11 in insulin-stimulated GLUT4 exocytosis (109,
449), and Rab 5 in GLUT4 endocytosis (206). Accordingly,
Rab5 has been localized to the cell surface (60, 439).
Interestingly, Rab4 and Rab11 seem to be differentially
localized: Rab4 is predominantly localized in a specialized
insulin-responsive preendosomal compartment uniquely
dedicated to the storage of GLUT4 (452), whereas Rab11
specifically associates with recycling endosomes in mam-
malian cell lines (392, 450). Both intracellular compart-
ments are known to participate in trafficking of GLUT4 in
muscle (8).
Only Rab11 has been found to participate in the
regulation of trafficking of fatty acid transporters. First,
Rab11 was found to be present in intracellular CD36
vesicles (308). Second, silencing of Rab11 in H9c2 cells
increased basal cell surface content of CD36 (and
GLUT4) (377). Since silencing of Rab11 did not alter the
stimulus-induced translocation of CD36, it appears that
Rab11 has a role in endocytotic rather than in exocy-
totic processes (377). This latter study provided the
first functional evidence for the role of Rab proteins in
CD36 trafficking. Moreover, Rab11 appears to play a
similar role in GLUT4 and CD36 translocation. Whether
the role of Rab5 in GLUT4 translocation could be ex-
trapolated to the translocation of CD36 or other fatty
acid transporters remains to be determined. It is, how-
ever, unlikely that Rab4 is involved in translocation of
fatty acid transporters, as this Rab member is associ-
ated with the insulin-responsive GLUT4 storage com-
partment (431), which is devoid of CD36 (see sect.
VA1).
C) COAT PROTEINS. Essentially nothing is known about
the involvement of coat proteins in CD36 trafficking, ex-
cept that caveolin-3 has been colocalized with CD36 at the
sarcolemma (236, 464). Its stimulatory role, if any, in fatty
acid uptake has already been discussed (see sect. IIID).
Another mechanism by which caveolin-3 could be posi-
tively involved in fatty acid uptake is that it clusters
t-SNARE proteins at the cell surface and, as a result, could
form a docking station for CD36 vesicles. This, however,
remains to be determined.
D) OTHER TRAFFICKING PROTEINS. Adaptor proteins assist
in the assembly of coat and SNARE proteins into fission
and fusion complexes as well as modulate the function
and intracellular localization of Rab proteins. These
adaptors also add an extra level of specificity for deliv-
ering the cargo to the appropriate subcellular address.
It is beyond the scope of this review to discuss the
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manner in which all these adaptors are involved in
GLUT4 translocation. Generally, the roles of these pro-
teins in the translocation of fatty acid transporters have
not yet been assessed, although evidence is beginning
to emerge that selected adaptors also function in CD36
translocation. One of these accessory proteins is
Munc18c, a member of the Sec1p-like/Munc18 family,
which functions in the transition of syntaxins (t-
SNAREs) into their open and closed states (111).
Munc18c forms a complex with syntaxin-4 (175) and is
known to be involved in GLUT4 translocation, as has
been shown in cell lines (429) and in skeletal muscle
from heterozygous Munc18c knockout mice (319). In
cardiac myocytes from heterozygous Munc18c knock-
out mice, Munc18c appeared to play a similar role in
CD36 and GLUT4 translocation, induced by either in-
sulin or AMPK activation, in that a 50% deletion did
not affect fatty acid or glucose uptake induced by each
of these metabolic stimuli. Hence, Munc18c appears to
be necessary, but not rate-limiting, in cardiac fatty acid
and glucose uptake under basal and stimulated condi-
tions (154). In addition, two adaptors for Rab11 have
been studied for their role in CD36 recycling (377).
Both adaptors belong to a family of Rab11 interacting
proteins (FIPs) with a conserved Rab11-binding do-
main. The first, FIP2, functions as an adaptor for direct
interaction of Rab11 with the motor protein myosin Vb
(158), and the second, Rip11, colocalizes with Rab11 in
endosomal membranes (339). Silencing of FIP2 in H9c2
cells enhanced the surface abundance of both GLUT4
and CD36, while silencing of Rip11 selectively en-
hanced surface CD36 (377). Hence, Rip11 is normally
involved in the intracellular retention of CD36, but not
of GLUT4, and this allows Rab11 to discriminate be-
tween CD36 and other cargo for trafficking purposes.
Interestingly, in adipocytes Rip11 has been reported to
be involved in insulin-stimulated GLUT4 translocation
possibly through interaction with AS160 (473), indicat-
ing that certain trafficking proteins fulfill different roles
in different tissues.
Taken together, it is clear that at present the
amount of information about signaling and trafficking
processes in translocation of fatty acid transporters is
at its infancy, yet information about these events is
beginning to accumulate. It appears that the trafficking
machinery is capable of selectively recruiting fatty acid
transporters from either insulin-responsive stores or
contraction-responsive stores, through as yet unidenti-
fied trafficking proteins that are specifically dedicated
to either of these stores. Knowledge about the protein
composition of the GLUT4 translocation machinery will
provide a framework for examining whether these pro-
teins are also involved in translocation of fatty acid
transporters. The identification of novel proteins in-
volved in signaling and trafficking of fatty acid trans-
porters would provide strategies to pharmacologically
regulate substrate fluxes. This may be especially impor-
tant for the treatment of metabolic diseases character-
ized by altered fatty acid metabolism in heart and skel-
etal muscle (see sect. VIIIB).
VI. CHRONIC PHYSIOLOGICAL REGULATION
OF FATTY ACID TRANSPORTERS
The expression and functioning of the membrane
fatty acid transporters is influenced by common physio-
logical stimuli. While in the previous section we focused
on acute effects (30 min), which can alter the subcellu-
lar localization of fatty acid transporters, in this section
we will discuss our current understanding of the long-
term effects, i.e., involving de novo protein synthesis.
These long-term effects are mediated by specific tran-
scription factors and coactivators.
Importantly, it should be remembered that proteins,
not mRNAs, are the functional unit for physiological pro-
cesses. The common assumption that fatty acid trans-
porter mRNAs are a suitable index of their protein prod-
uct is problematic. For example, changes in fatty acid
transporter mRNAs frequently do not correlate either
with changes in their protein expression or with changes
in the rate of fatty acid transport in many experimental
models (27, 28, 44, 71, 273, 277, 278, 281, 443, 479), indi-
cating a prominent role for posttranscriptional processes.
These studies also illustrate that extrapolation of mRNA
data to functional consequences can result in interpretive
and conceptual errors. Therefore, it is preferable to ex-
amine fatty transporters at the level of their protein ex-
pression, although even such data are limiting given that
fatty acid transporters can traffic between subcellular
compartments (see sect. IV). After all, just as for GLUT4,
the functional pools of fatty acid transporters are those at
the plasma membrane.
A. Regulation of Fatty Acid
Transporter Expression
Like many proteins involved in lipid transport and
metabolism, the expression of most, if not all, membrane
fatty acid transporters is under the transcriptional control
of nuclear peroxisome proliferator-activated receptors
(PPAR) in a tissue-specific manner. Depending on the
presence of (one or more of) the three PPAR subtypes, ,
/, and 	, cells will respond to specific PPAR agonists by
transcriptionally upregulating the expression of fatty acid
transporters. For instance, synthetic agonists for PPAR
(known as fibrates) induce CD36 expression in the heart
(19), while CD36 expression is significantly decreased in
hearts and muscle of the PPAR null mouse (307). Be-
cause PPAR	 is expressed in skeletal muscle but virtually
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absent in heart (19), CD36 expression was found sensitive
to regulation by PPAR	 agonists in human skeletal muscle
(70) but not in rat cardiac myocytes (454). Fatty acids and
selected fatty acid metabolites are the physiological li-
gands for the PPARs, allowing mammalian cells to up-
regulate fatty acid transporters and the lipid metabolic
machinery in case of increased exposure to fatty acids, so
to create a vicious cycle of increased exposure and utili-
zation (for review, see Refs. 291, 398).
While initial studies had concluded that the promoter
region of CD36 contains a peroxisome proliferator-re-
sponsive element (PPRE) (433), subsequent studies re-
vealed the absence of PPRE in the responding upstream
promoter region and showed that transcriptional activa-
tion of the CD36 gene by PPAR ligands is indirectly de-
pendent on PPAR (369). This would also explain the
delayed transcriptional activation of CD36 expression by
PPAR ligands, compared with other PPAR target genes
(369). With respect to the other fatty acid transporters, a
functional PPRE has been identified in the promoter re-
gion of FATP1 (129) and likely is also present in the
promoter of the other FATPs. In line with this, PPAR
activators were found to coordinately regulate the expres-
sion of FATP1 and acyl-CoA synthetase in rat tissues (293).
The presence of a PPRE in the promoter of FABPpm has not
been reported, but is likely as PPAR	 activation induced the
expression of FABPpm in rat skeletal muscle (22).
More recent studies have disclosed that overexpres-
sion of the PPAR	 coactivator 1 (PGC-1) increased the
expression of CD36 (23, 82), as well as GLUT4 (23), in rat
muscle, together with an increase in mitochondrial fatty
acid oxidation (22). Finally, CCAAT/enhancer binding
protein  (C/EBP) was found to regulate CD36 gene
expression at the transcriptional level (341), but the role
of this transcription factor most likely is restricted to
adipocytes, especially during the differentiation of these
cells.
Taken together, fatty acids and specific metabolites
are now recognized to modulate the expression of multi-
ple genes, notably those involved in fatty acid metabo-
lism, in a PPAR-dependent manner. Fatty acids as signal-
ing molecules thereby “prepare” the cell for the uptake
and utilization of larger amounts of fatty acids. Fatty acid
transporters take part in this process in a special fashion
as they could promote a positive-feedback loop to further
increase gene transcription.
B. Effects of Development, Ageing, and Gender
1. Development and ageing
The oxidation capacities and mitochondrial enzymes
of heart and muscle increase quickly during development,
reaching adult values at 15–20 days postnatally in heart
(144) and by 35 days in skeletal muscle (47). A similar
rapid adaptation (days 10–35) was observed in CD36
protein expression in rat heart and muscle, while FABPpm
protein expression was unaltered in the heart and was
reduced somewhat in muscle (47). Thereafter, CD36 ex-
pression and mitochondrial enzyme activity remained in-
variant from 5 to 52 wk (47). The increases in fatty acid
transport in the transition from the neonatal period (day
10) to the adult stage was attributable to concomitant
increases in plasmalemmal CD36 in heart, and to plas-
malemmal CD36 and FABPpm in muscle.
In older rats (15–24 mo vs. 5 mo), fatty acid oxidation
was reduced while esterification was increased (441). The
concurrent changes in fatty acid transporters were not
detailed except to note that FABPpm expression was in-
creased (441). Similarly, in hearts of aged mice (52 wk),
there is a twofold increase in intramyocardial lipid accu-
mulation, as well as a 50% reduction in fatty acid oxi-
dation (254), which is accompanied by a dramatic in-
crease in CD36 (4-fold) in these aged murine hearts com-
pared with young hearts. This suggests that CD36 is a
mediator of multiple metabolic, functional, and structural
alterations in the aged heart, particularly since hearts
from aged CD36 null mice were found to have lower
intramyocardial lipid concentrations and enhanced car-
diac function compared with the aged wild-type mice
(254).
Taken together, it appears that myocardial fatty acid
uptake increases to a higher level at both ends of the life
span, i.e., perinatally and during ageing, effects that ap-
pear to be mediated in part by the upregulation of CD36.
While in the neonate the increase in CD36 would seem to
be positively associated with the capacity to oxidize fatty
acids, it appears that in the aged animals the further
upregulation of CD36 allows the uptake of fatty acids to
outpace the capacity for fatty acid oxidation. This then
leads to deleterious metabolic consequences in heart and
muscle of aged animals, which resemble those observed
in insulin resistance and type 2 diabetes in which CD36-
mediated fatty acid transport also exceeds the capacity
for oxidation (see sect. VIIB).
2. Gender differences
Fatty acid metabolism has long been suspected to be
greater in females than in males. This gender difference
has been addressed in a recent review, particularly as it
applies to skeletal muscle triacylglycerol esterification
and oxidation (242). Although a number of fatty acid
transporters are coexpressed in rat and human muscle,
including FABPpm, CD36, FATP1, and FATP4 (45, 46, 219,
445), it has been difficult to demonstrate that there are
gender differences in fatty acid transporters in skeletal
muscle. For example, CD36 protein expression was some-
what higher in women than in men (244), but this was not
observed in another study (389). Gender differences have
392 GLATZ, LUIKEN, AND BONEN
Physiol Rev • VOL 90 • JANUARY 2010 • www.prv.org
Downloaded from journals.physiology.org/journal/physrev at Universiteit Maastricht (137.120.149.252) on September 27, 2021.
not been observed in FABPpm protein expression or
FATP1 mRNA (244, 384). However, there appear to be
gender-related sensitivities in CD36 responses to fatty
acid infusion, since in male, but not female rats, fatty acid
infusion induced insulin resistance and reduced muscle
CD36 total protein by 50% (189). Similarly, it has been
observed that FABPpm protein expression is increased in
endurance-trained men but not endurance-trained women
(244). Some of these discrepant findings between men
and women may be related to difficulty in matching the
sexes appropriately and/or the criteria that are employed
for matching individuals.
C. Effects of Fasting, Hormones, and
Exercise Training
1. Fasting
Several studies have shown that fasting alters fatty
acid metabolism in heart and skeletal muscle. For exam-
ple, short-term fasting (12–48 h) increased FABPpm pro-
tein at the plasma membrane by 60% (444). Similarly, 48 h
of fasting increased CD36 expression in the heart (2-
fold) (455) and in skeletal muscle (20%). The fasting-
induced upregulation of CD36 mRNA and protein, as well
as other genes involved in lipid metabolism, is AMPK
	3-dependent (269).
2. Insulin
In cardiac myocytes, insulin not only (acutely) in-
duces the translocation of CD36, but also relatively rap-
idly (2 h) increases the expression of CD36 protein, but
not FABPpm (72). Similarly, CD36 protein content was
increased 1.5-fold in human muscle after 3 h of insulin
stimulation (94). In the studies in perfused hearts and
cardiac myocytes there were similar insulin-induced in-
crements in CD36 protein expression (cardiac myocytes
43%; Langendorff-perfused hearts 32%) and in plas-
malemmal protein content (29%) and rates of fatty acid
transport (34%) (72). Thus CD36 expression is highly
responsive to insulin stimulation, although in insulin-re-
sistant individuals with increased circulating concentra-
tions of insulin, only the plasmalemmal content of CD36
expression is increased, not total CD36 protein expres-
sion (48).
2. Leptin
It is well documented that leptin acutely increases
fatty acid utilization by activating AMPK in skeletal mus-
cle (302, 309, 310, 403–406). Leptin appears to induce the
translocation of CD36 from an intracellular depot to the
plasma membrane (305, 324), thereby increasing fatty
acid uptake and providing the necessary substrate for
fatty acid oxidation. In contrast, prolonged leptin infusion
(2 wk) downregulated FABPpm and CD36 protein expres-
sion as well as their plasmalemmal contents in skeletal
muscle, resulting in a parallel reduction in fatty acid
transport (404). This long-term effect of leptin may have
been a compensatory response. Similarly, in adipocytes of
ob/ob mice, prolonged leptin treatment (21 days) reduced
FABPpm and CD36 mRNAs and normalized fatty acid
uptake (121). Clearly, leptin exerts profound effects on
fatty acid transport and transporters, although the acute
and chronic effects of this adipokine differ.
3. Exercise training
Short-term electrically stimulated muscle contrac-
tion, and likely also acute volitional exercise, have been
described in section IV to stimulate both fatty acid and
glucose utilization via translocation of GLUT4, CD36,
FABPpm, FATP1, and FATP4 (44, 219, 277, 443) but not
FATP6 (219) to the plasma membrane. In contrast, it is
well known that endurance exercise training shifts fuel
selection both at rest and during exercise towards fatty
acid oxidation and esterification, as training-induced
adaptive responses include increased activity of enzymes
involved in fatty acid oxidation and esterification, as well
as intramuscular triacylglycerol accumulation (40, 113,
196, 215, 242, 374, 457). Because exercise training does
not increase the circulating concentrations of fatty acids,
it seems feasible that an increase in fatty acid transport
proteins supports the enhanced capacity for fatty acid
metabolism in trained skeletal muscle.
In rats, exercise training failed to alter the expression
of either CD36 or FABPpm total proteins in the heart
despite the fact that fatty acid oxidation was increased
(61). This may suggest perhaps that these proteins were
redistributed in the cell to increase the plasmalemmal
content, as this has previously been shown to account for
the increased fatty acid oxidation in murine db/db hearts,
in which fatty acid oxidation is markedly increased (65).
Increasing muscle activity with exercise training (447)
or 7-day chronic low-frequency stimulation of the peroneal
nerve (41, 252) increased both CD36 and FABPpm protein
expression and their plasma membrane contents, as well
as increasing the sarcolemmal transport rate of fatty acids
(41, 252, 447). The increase in fatty acid transport (1.9-
fold) matched the increase in fatty acid metabolism (1.9-
fold, sum of oxidation and esterification) (41). Induction
of muscle inactivity (7-day denervation) lowered rates of
fatty acid transport, but this was due to a reduction in
plasma membrane CD36 and FABPpm, while there was no
change in their total protein expression levels (252) (Fig. 6).
Taken together, these findings indicate that fatty acid trans-
port can be regulated by several mechanisms, i.e., 1) by
altering the total protein expression of CD36 and FABPpm
and their contents at the plasma membrane (exercise train-
ing or chronic muscle stimulation), or 2) by altering their
FATTY ACID TRANSPORTERS AND LIPID METABOLISM 393
Physiol Rev • VOL 90 • JANUARY 2010 • www.prv.org
Downloaded from journals.physiology.org/journal/physrev at Universiteit Maastricht (137.120.149.252) on September 27, 2021.
presence at the plasma membrane, without altering protein
expression (denervation). Indeed, the functional pool of
fatty acid transporters are those at the plasma membrane,
since the up- and downregulation in fatty acid transport in
chronically stimulated and 7-day denervated muscle corre-
lated highly with the plasmalemmal contents of CD36 and
FABPpm (252) (Fig. 6).
Exercise training studies in humans have shown vari-
able responses with respect to adaptive changes in the
protein expression of CD36 and FABPpm. In some studies
exercise training has increased CD36 but not FABPpm
(63% VO2peak; Ref. 442). Others have shown, applying a
one-leg knee extension training model in which the con-
tralateral muscle serves as control, that FABPpm protein
expression is increased (CD36 was not measured; Ref.
243). These different effects observed may be exercise-
intensity dependent, as with high-intensity exercise train-
ing (90% VO2peak) there was only an increase in FABPpm
but not CD36 (423), while with very-high-intensity exer-
cise (100% VO2peak) that is largely dependent on glyco-
gen utilization no changes were observed in either CD36
or FABPpm protein expression, but increases did occur in
other transport proteins (GLUT4, MCT-1 and -4; Ref. 62).
Upregulation of fatty acid transporters CD36 and FABPpm
may also be influenced by the dietary state during train-
ing. For example, providing a high carbohydrate-rich
breakfast before training failed to result in any training-
induced changes in CD36 and FABPpm (100). This con-
trasted markedly with training in the fasted state, when
the demands on fatty acid metabolism are greater, as this
increased (20%) both CD36 and FABPpm protein expres-
sion coordinately (r  0.63) (100). It may be important in
future studies to determine whether fatty acid transport-
ers have been relocated to the plasma membrane and/or
to the mitochondria, in the absence of any changes in
their expression. Subcellular relocation of fatty acid
transporters without a change in their protein expression
have been observed in denervated muscle (see above)
(252) and in muscles from obese animals (273) and hu-
mans (48) (see sect. VIIB).
VII. ALTERATIONS IN FATTY ACID
TRANSPORTERS IN DISEASE
In view of the general significance of membrane fatty
acid transporters for whole body lipid metabolism and
specifically their role in the acute regulation of cellular
fatty acid uptake in muscle and heart, it is to be expected
that changes in cellular lipid metabolism such as occur in
disease states will be accompanied by concomitant adap-
tations in the expression and/or subcellular location of
selected fatty acid transporters. On the other hand,
changes in fatty acid transporter content or functioning,
as may be caused by nutritional, hormonal, or pharmaco-
logical stimuli, will likely have an impact on whole body
lipid metabolism. Examples of both such alterations, with
a primary focus on heart and muscle, will be discussed in
this section. These findings also begin to suggest that
membrane fatty acid transporters may be exploited as
therapeutic targets.
A. Cardiac Hypoxic Disease and Heart Failure
The heart can use a variety of metabolic substrates
to cover its demand for energy, and it has the capacity to
rapidly switch among these substrates in response, e.g., to
changes in their supply, actions of hormones and cyto-
kines, and the availability of oxygen (400). In normal
conditions, cardiac metabolic energy is provided from the
oxidation of long-chain fatty acids (40–60%), glucose
(30–50%), and lactate (10%). In hypoxic conditions, as
caused acutely by an ischemic insult or myocardial
infarction, the heart switches to the substrate with the
highest oxygen efficiency, i.e., carbohydrates, provided
from glucose and endogenous cardiac glycogen. During
reperfusion, when oxygen supply is reinstated, there is
a progressive increase in the contribution of fatty acids
to ATP production. In chronic cardiac disease and heart
failure, the changes in substrate preference are more
permanent and are accompanied by alterations in the
expression of metabolic enzymes and proteins. Such
chronic changes might influence the so-called meta-
bolic flexibility of the heart, i.e., the ability to switch to
other energy substrates and to better withstand an
acute metabolic stress (140, 400).
1. Acute changes
The acute switch in substrate utilization that occurs
during short-term hypoxia, i.e., an increased contribution
FIG. 6. Chronically altered muscle contractile activity affects the
rate of fatty acid uptake and plasmalemmal CD36 and FABPpm. Rat
hindlimb muscles were chronically stimulated (7 days) or denervated (7
days) whereafter fatty acid transport into giant sarcolemmal vesicles
and plasmalemmal CD36 (left) and FABPpm (right) content were deter-
mined. FATPs were not studied. [Redrawn from Koonen et al. (252).]
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from carbohydrates and decreased contribution from
fatty acids to energy production, appears not be accom-
panied by a decreased sarcolemmal presence of fatty acid
transporters, which would be expected to lower fatty acid
uptake. Instead, studies with rat myocytes and perfused
hearts show that acute hypoxia activates AMPK, which
induces the translocation of both CD36 and FABPpm to
the sarcolemma leading to a concomitant increase in the
rate of fatty acid uptake (74). Because of the reduced rate
of fatty acid oxidation, a large portion of the incoming
fatty acids are redirected into intracellular lipid pools.
These observations reveal a role for CD36 and FABPpm in
intramyocardial lipid accumulation that occurs in the fail-
ing heart and that is associated with cardiac contractile
dysfunction (380) (see sect. VIIB).
During reperfusion following an ischemic insult,
there is a shift towards increased fatty acid utilization.
Whether CD36 serves a beneficial or detrimental role
during this transition has been studied by two groups of
investigators. Irie et al. (216) reported that isolated
working hearts from CD36 null mice showed a 40%
lower postischemic recovery of cardiac function com-
pared with hearts from wild-type littermates. Hearts
from mice reexpressing CD36 in heart and skeletal
muscle under the muscle creatine kinase promoter
showed an ischemic tolerance comparable to that of
wild-type hearts, further indicating that the decreased
tolerance in CD36 null mice is directly caused by CD36
deficiency (216). Dietary intervention with medium-
chain fatty acids to circumvent the CD36-mediated up-
take resulted in normalization of the ischemic tolerance
of CD36 null hearts. These observations led the authors
to suggest that the presence of CD36 is crucial to
upregulating fatty acid uptake and cardiac energy pro-
duction during the transition from ischemia to reperfu-
sion and, therefore, that CD36 is a determinant of ische-
mic tolerance of the heart. In contrast, a subsequent
comparable study (258) reported that the postischemic
recovery of CD36 null hearts is not different from that
of wild-type hearts and that during reperfusion accel-
erated glucose oxidation can compensate for the loss of
fatty acid-derived ATP (258) (Fig. 7). Most likely, these
conflicting observations are explained by differences in
energetic status of the hearts before ischemia, namely,
there was a 40% lower content of both ATP and glyco-
gen in the CD36 null hearts relative to wild-type hearts
in one study (216) but not the other (258). Taken to-
gether, these two studies suggest that a deviation in the
normal contributions of glucose and fatty acid oxida-
tion to cardiac energy production, for instance, towards
a markedly increased dependence on glucose oxidation
as seen in CD36 null hearts (258), will not affect cardiac
ATP production when adequately perfused. In contrast,
such a chronic change in cardiac substrate preference
renders the heart more susceptible to stressors like an
ischemic insult when a lower ATP production rate may
depress cardiac function. Furthermore, substrate trans-
porters provide dynamic regulation of substrate uptake
and thus add to the metabolic flexibility of the heart.
2. Chronic changes
The development of cardiac hypertrophy and heart
failure is associated with changes in cardiac substrate
preference, namely, glucose utilization is increased at the
expense of fatty acids (10, 400). In the postinfarction rat
heart, this change in substrate preference is reflected in
an upregulation of GLUT1 and downregulation of genes of
lipid metabolic enzymes and of fatty acid transporters (181,
359). Specifically, the myocardial contents of FABPpm,
CD36, FATP1, and FATP6 protein expression were each
reduced with a parallel decrease in palmitate oxidation
rate and in cardiac ejection fraction (181). These data
suggest that fatty acid transporters may be involved in the
transition away from fatty acid metabolism in heart fail-
ure, but it should be noted that the subcellular localiza-
tion of the transporters was not examined in either of
these studies.
Likewise, fatty acid transporter deficiency, which
will limit cardiac fatty acid utilization and elicit an in-
crease in glucose utilization, is associated with the devel-
opment of cardiac hypertrophy (216, 313). This parallels
the effect of pharmacological inhibition of mitochondrial
-oxidation, which also leads to increased glucose utili-
zation and ultimately to cardiac hypertrophy (54, 360).
FIG. 7. Changes in substrate utilization in hearts from CD36 null
mice. Rates of palmitate oxidation (left), glucose oxidation (middle),
and tricarboxylic acid (TCA) cycle acetyl-CoA production (right) were
determined in wild-type and CD36 null mouse hearts perfused as work-
ing hearts with 1.2 mM palmitate and 5 mM glucose. TCA cycle activity
was calculated from the rates of palmitate and glucose oxidation, using
8 mol acetyl-CoA for every 1 mol palmitate oxidized and 2 mol acetyl-
CoA for every 1 mol glucose oxidized. The lower palmitate oxidation
seen in hearts from CD36 null mice is compensated by an increase in
glucose oxidation so that these hearts are not energetically compro-
mised. [Redrawn from Kuang et al. (258), with permission from the
American Heart Association.]
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For example, CD36 null mice on a regular diet develop
cardiac hypertrophy (216, 313), but interestingly, FATP1
null mice do not (up to 15 mo of age) (245). Chronic (12
wk) intraperitoneal administration of SSO, a selective in-
hibitor of CD36-mediated fatty acid uptake (93, 153), caused
cardiac hypertrophy (260). Conversely, aged (1 yr) mice de-
veloped cardiac hypertrophy in the face of a greater than
fourfold increase in total myocardial CD36 protein ex-
pression in aged animals (254), but in this study neither
sarcolemmal CD36 nor fatty acid uptake was determined,
hampering the interpretation of the data. Nevertheless,
when taken together, the above findings suggest that fatty
acid transporters are mediators of substrate-induced car-
diac remodeling.
A role for CD36 deficiency in the development of
cardiac hypertrophy was suggested from studies with a
strain of spontaneously hypertensive (SHR) rats main-
tained in North America (7, 157). However, it appears that
these animals are not CD36 deficient, and fatty acid up-
take is not compromised (43) (see sect. VIIB). Thus car-
diac hypertrophy in this model is attributable to other
factors.
3. Human studies
There is some evidence to suggest that the link be-
tween CD36 expression and cardiac hypertrophy and pos-
sibly tolerance to ischemia, as observed in rodent models,
can also be extended to humans. A Japanese study re-
vealed that 40% of patients with hypertrophic cardiomy-
opathy carry mutations in CD36 leading to a negligible or
markedly reduced CD36 protein expression (320, 425).
Mutations leading to CD36 deficiency are rare in Cauca-
sian populations (0.3%), but these are at least 10 times
more frequent (3–6%) in Asian, African, and African-
American populations (98, 262, 271). These CD36 muta-
tions were shown to lead in almost all cases to severe
reductions in myocardial long-chain fatty acid uptake
(320, 425), which metabolic change may have triggered
the hypertrophic response as seen in the animal studies
described above. On the other hand, a subsequent study
(424) showed that patients with a total defect in myocar-
dial fatty acid uptake, which in all cases was associated
with the absence of CD36, do not always develop hyper-
trophic cardiomyopathy (424). This latter finding and the
broad spectrum of clinical manifestations of hypertrophic
cardiomyopathy may explain why another study reported
that the incidence of CD36 deficiency in hypertrophic
cardiomyopathy patients is not higher than in the general
population (311). Clearly, the development of heart dis-
ease in humans is complex, and the association between
CD36 expression and heart function and failure needs
further exploration, whereby special attention should be
given to the functional presence of CD36 on the sarco-
lemma and its association with mitochondria.
B. Insulin Resistance and Type 2 Diabetes
Insulin resistance and type 2 diabetes are associated
with changes in lipid metabolism. For example, there is a
strong association between skeletal muscle insulin resis-
tance and 1) plasma fatty acid concentrations (36–38)
and 2) intramuscular triacylglycerol depots (220, 221, 256,
326, 409). However, intramuscular triacylglycerol depots
are an indirect marker of insulin resistance, since the
more soluble lipid metabolites such as ceramides, diacyl-
glycerols, and long-chain fatty acyl-CoAs interfere with
the postreceptor insulin signaling cascade (77, 78, 90, 193,
194, 410, 421). This excessive accumulation of intramyo-
cellular fatty acids and their metabolites has been re-
ferred to as lipotoxicity and is a main contributor to the
pathophysiology of insulin resistance and dysfunctioning
of heart and skeletal muscle (194, 451). The pathological
state of the lipid-overloaded, insulin-resistant, and failing
heart is commonly referred to as diabetic cardiomyopathy
(1, 400). Several recent reviews discuss in detail the de-
fects in postreceptor insulin signaling mechanisms (1,
194, 207, 428) that are at the root of fatty acid-induced
insulin resistance in skeletal muscle and the heart in
obesity and type 2 diabetes.
Fatty acids that are taken up into heart and skeletal
muscle are primarily oxidized or stored as triacylglycer-
ols. As long as the fatty acid uptake and partitioning
remains appropriately balanced, metabolic dysregulation
does not occur. However, these processes are unbalanced
toward lipid accumulation in insulin-resistant skeletal
muscle (18, 48, 164) and the heart (322, 380). This increase
in intracellular lipid accumulation would not seem to be
simply attributable to a concomitant reduction in (mito-
chondrial) fatty acid oxidation as has been speculated
(238), since there is no consistent evidence in support of
this notion (for review, see Ref. 195). For example, in
heart and skeletal muscles of high fat fed rats, db/db mice,
obese Zucker rats, and ZDF rats fatty acid oxidation is
either reduced slightly (18, 164, 322), unaltered (387, 482),
or increased (65, 66, 91, 446). In muscle from obese
humans, a reduction in skeletal muscle fatty acid oxida-
tion is at times observed (202, 210, 246, 430), but not
always (48, 405). In individuals with type 2 diabetes,
whole muscle fatty acid oxidation also appears to be
reduced (18), and basal mitochondrial oxidative phos-
phorylation was reduced in insulin-resistant offspring of
patients with type 2 diabetes (331). In obese individuals,
the reduction in fatty acid oxidation appears to be corre-
lated with the extent of obesity (BMI) (430) and has also
been attributed to a reduced mitochondrial content (202,
246, 384), as fatty acid oxidation by isolated mitochondria
of obese individuals was normal (202) and not impaired as
had been suggested previously based on indirect assess-
ment of mitochondrial fatty acid oxidation (237, 355).
Similarly, in individuals with type 2 diabetes, reductions
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in muscle fatty acid oxidation and oxidative phosphory-
lation appear to be a result of reduced mitochondrial
content, possibly as a result of diminished physical activ-
ity, rather than an intrinsic defect in their mitochondria
(50, 101, 304, 331, 342), especially since in isolated mito-
chondria respiratory function, mitochondrial citrate syn-
thase, and -HAD activities were normal, as was the rate
of palmitoyl-L-carnitine oxidation (50, 304). It has been
suggested recently that obesity-related insulin resistance
in skeletal muscle is associated with an inability of mito-
chondria to oxidize the excess influx of fatty acids, which
leads to an accumulation of intramuscular lipids (255).
We (197) have examined this question as described fur-
ther in section VIIB2.
In conclusion, observations in some studies that mi-
tochondrial fatty acid oxidation may be increased at times
suggests that factors other than simply a reduction in fatty
acid oxidation can contribute to the intramuscular lipid
accumulation, particularly 1) an increased delivery of
circulating fatty acids, such as is frequently observed in
obesity, and/or 2) an increased rate of in fatty acid trans-
port, facilitated by an increase in fatty acid transporters.
Importantly, in cases that reductions in fatty acid oxida-
tion in insulin-resistant skeletal muscle were reported,
these reductions reflect reductions in mitochondrial con-
tent rather than impairments in the intrinsic ability of
mitochondria to oxidize fatty acids.
1. Permanent subcellular relocation of fatty
acid transporters
A) ANIMAL MODELS OF INSULIN RESISTANCE. Studies examin-
ing the rates of fatty acid transport have been performed
in animal models of high-fat diet-induced insulin resis-
tance (182, 322), in obese (Zucker obese fa/fa) (197, 273)
and type 2 diabetic rats (Zucker diabetic fatty, ZDF) (27,
71, 91), and in murine models of obesity (28, 150). These
studies have shown that fatty acid uptake rates were
increased in key metabolic tissues, including 1) hearts of
obese Zucker rats (40–90%; Refs. 27, 91, 273), ZDF rats
(120%; Ref. 27), and rats fed a high-fat diet (43%; Ref. 322);
and 2) skeletal muscle of high fat fed rats (40–80%; Ref.
182), obese Zucker rats (80%; Ref. 273), in red but not
white muscle of ZDF rats (66–99%; Ref. 71), and in rats
fed a high-sucrose diet during the suckling period (50%;
Ref. 211). Thus, in all models of insulin resistance, fatty
acid transport is upregulated in heart and skeletal muscle.
This upregulation is already present in muscles of 6-wk-
old ZDF rats, before the onset of type 2 diabetes (71). It
appears that upregulation of fatty acid transport is a
predisposing factor to obesity and insulin resistance.
However, the underlying mechanisms promoting fatty
acid transport appear to differ depending on the severity
of insulin resistance (see below).
B) MODEST AND MODERATE INSULIN RESISTANCE. In models of
modest (high-fat diet; Refs. 182, 322) to moderate insulin
resistance (obese Zucker rats; Refs. 91, 164, 273), the
increased rates of fatty acid transport in heart and muscle
in general were not related to the increased expression of
fatty acid transporter proteins (CD36 and FABPpm) in
these tissues (91, 211, 273, 322). However, there was a
marked increase in the content of the functional pool of fatty
acid transporters, i.e., those at the plasma membrane in
heart (CD36, 60–74%; FABPpm, 50%) (91, 273) and in
skeletal muscle (CD36, 33–80%; FABPpm, 0–14%), (164,
211, 273). This “permanent relocation” of CD36 to the
plasma membrane in skeletal muscle has been confirmed in
more recent studies, which also demonstrated that such
changes were not observed for plasmalemmal FABPpm,
FATP1, and FATP4 (197). Thus these studies have revealed
a previously unknown mechanism that increases fatty acid
uptake in modest and moderate models of insulin resistance.
Specifically, CD36 and FABPpm are permanently relocated
from their intracellular depots to the cell surface in heart
(91, 273), while in skeletal muscle such a permanent reloca-
tion was mainly observed for CD36 only, not FABPpm,
FATP1 or FATP4 (164, 197, 273).
C) SEVERE INSULIN RESISTANCE. In ZDF rats, which
progress rapidly from insulin resistance (week 6) to se-
vere type 2 diabetes (week 24) (71, 466, 467), there was
an increase in the rate of fatty acid transport and the
CD36 protein expression and plasmalemmal content
compared with age-matched, nondiabetic animals (71).
Similarly, in female ZDF rats, which develop diabetes
when fed a high-fat diet, there was also an increase in
muscle CD36 protein expression and plasmalemmal
content (387). However, concurrent treatment with
metformin or exercise impaired the increase in CD36
protein expression and plasmalemmal content, and this
was associated with reductions (relative to the high-fat
diet) in circulating glucose and in intramuscular cer-
amide and diacylglycerol contents. This study (387)
begins to suggest that reducing plasmalemmal CD36
reduces the severity of intramuscular lipid accumula-
tion and hyperglycemia.
D) METABOLIC EFFECTS OF IMPAIRED CD36 TRANSLOCATION ON
FATTY ACID METABOLISM. Presumably, the insulin resistance in
CD36 signaling/trafficking accounts, in part, for the inabil-
ity of insulin to further stimulate triacylglycerol esterifi-
cation in obese Zucker rat heart and muscle, beyond the
already increased rates observed under basal conditions
(91, 164). This, however, is not apparent during contrac-
tion (muscle) or AMPK activation (heart), as the normal
FABPpm translocation (164), along with the already up-
regulated plasmalemmal CD36 (91, 164), seems to provide
the needed fatty acid transport capacity to upregulate
fatty acid oxidation rates in obese animals. This begins to
imply that an increase in both plasmalemmal CD36 and
FABPpm contribute to the upregulation in contraction-
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stimulated fatty acid oxidation. Indeed, some tentative
preliminary evidence for this has been shown in skeletal
muscle into which CD36 and FABPpm were cotransfected
(314).
2. Key role of CD36 in insulin resistance
In the type 2 diabetic heart (db/db mice), the in-
creased expression (50%) and plasmalemmal content of
CD36 (75%), and possibly the small change in plasmalem-
mal FABPpm (18%), were positively correlated with the
increased rates of fatty acid esterification (2-fold). All
other parameters involved in regulating lipid metabolism
(CPT-I activity, CPT-I sensitivity to inhibition by malonyl-
CoA, UCP3 expression) were either unaltered or reduced
(AMPK activity) (65). This suggests that in rodent models
deficient in leptin signaling, alterations in sarcolemmal
fatty acid transporters rather than alterations in mito-
chondrial -oxidation are responsible for cardiac lipid
accumulation and, subsequently, loss of cardiac function.
More direct evidence for the role of CD36 in in-
creased fatty acid esterification and lipid accumulation in
the insulin resistant heart was obtained with pharmaco-
logical and genetic experiments to block CD36. In cardiac
myocytes of high fat fed rats (322) and obese Zucker rats
(91), blocking CD36-mediated fatty acid uptake in these
insulin-resistant tissues (91, 322), using the specific CD36
inhibitor SSO, lowered the augmented rate of fatty acid
esterification. A similar effect occurred when CD36 was
ablated in a model of lipotoxic cardiac myopathy (480).
This indicates that the upregulation of CD36 at the plasma
membrane in insulin resistance is a key factor contribut-
ing to the accumulation of intracellular lipids.
A) TIME COURSE OF CD36 RELOCATION. As established in the
heart and muscle, the permanent CD36 relocation to the
plasma membrane is an early event in the development of
insulin resistance and cardiomyopathy. Importantly, it
has been observed that the increase in CD36-mediated
fatty acid uptake in cardiac myocytes precedes changes in
glucose uptake. Namely, in cardiac myocytes from insu-
lin-resistant prediabetic obese Zucker rats, CD36 translo-
cation and increased basal fatty acid uptake occurred in
the absence of changes in basal and insulin-stimulated
glucose uptake (92). Upon the transition from insulin
resistance to type 2 diabetes, as seen in high fat fed rats
(322) and diabetic Zucker rats (Luiken et al., unpublished
results), CD36 translocation and increased basal fatty
acid uptake are accompanied by concurrent decreases in
basal and insulin-stimulated glucose uptake. Hence, dur-
ing the development of diabetes there will be an increased
juxtaposed localization of CD36 and GLUT4, with CD36
being at the cell surface and GLUT4 being localized intra-
cellularly (Fig. 8). Moreover, it has been known for some
time that the insulin-sensitive glucose transporter GLUT4
is retained within the intracellular depot(s) in obese skel-
etal muscle in animals (57, 58) and in humans (12, 361).
The strong inverse relationship [r  	0.91 (71) and r 
	0.94 (387)] between plasmalemmal GLUT4 and CD36 in
insulin-resistant skeletal muscle in several studies is strik-
ing (71, 387) and contrasts with the healthy situation, in
which CD36 and GLUT4 have been found each to be
equally distributed between endosomes and the sarco-
lemma (see sect. IVA). These combined findings suggest
that in the healthy heart and muscle CD36 and GLUT4 are
stored in separate subcompartments of the recycling en-
dosomes and that these transporters are recruited via
signaling and/or trafficking proteins specific for either one
of these transporters. Then, upon development of insulin
resistance, alterations in the signaling and/or trafficking
proteins specifically dedicated to CD36 translocation
could result in a selective and permanent CD36 translo-
cation to the sarcolemma, without a change in subcellular
distribution of GLUT4. Indeed, evidence for the existence
of signaling and/or trafficking events that are specifically
associated with CD36 has recently been reported when
the small Ras-like GTPase rab 11 (see sect. VB) was
observed to be attached to endosomal CD36 vesicles and
not to GLUT4 vesicles (308).
Permanent CD36 relocation to the sarcolemma has
also been shown to precede the loss of cardiac function,
as 4 wk of high-fat feeding already resulted in increased
cell surface localization of CD36 in the absence of a
decrease in cardiac functional parameters, whereas a
high-fat diet for 8 wk showed sustained surface presence
of CD36 concomitant with decreased cardiac functioning
(322). In combination with the causal relationship of in-
creased sarcolemmal CD36 abundance and intramyocel-
lular lipid accumulation, CD36 is beginning to be regarded
as a key factor in the development of type 2 diabetes in
heart and muscle.
B) CD36 AND FATTY ACID TRANSPORT CONTRIBUTE TO INTRAMUS-
CULAR LIPID ACCUMULATION, NOT REDUCED FATTY ACID OXIDATION.
In view of a developing consensus that intramuscular
lipids can accumulate in muscle despite concurrent in-
creases in fatty acid oxidation, we have compared rates of
CD36-mediated fatty acid transport with rates of fatty
metabolism in muscles of obese Zucker rats (197). These
studies have shown that plasmalemmal CD36 was again
permanently relocated to the plasma membrane (197), as
we had shown previously in this model (273). This plas-
malemmal increase in CD36 in muscle of obese animals
was highly correlated with an increased rate of fatty acid
transport into muscle. Concomitantly, the rates of fatty
acid esterification and oxidation were also both in-
creased. However, in relation to the increased rate of fatty
acid transport, the rate of esterification was eightfold
greater than the increase in fatty acid oxidation (197).
These studies strongly suggest that fatty acid transport
into muscle cell is in excess of the capacity for them to be
oxidized and, hence, lipids accumulate within the muscle
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(197). Thus the CD36-mediated increase in fatty acid
transport, rather than alterations in fatty acid oxidation, is
the key factor contributing to the increase in intramuscu-
lar lipid accumulation in insulin-resistant muscle.
C) MECHANISMS RESPONSIBLE FOR PERMANENT CD36 RELOCATION
TO THE SARCOLEMMA. As detailed in sections IVA and V, in the
healthy heart and skeletal muscle, fatty acid uptake is
increased by insulin or by contraction due to transloca-
tion of CD36 from insulin-responsive PI3K/PKB/Akt-me-
diated endosomal stores or from contraction-responsive
AMPK-mediated endosomal stores, respectively, to the
sarcolemma. In the insulin-resistant heart, insulin was
unable to further increase the already elevated basal fatty
acid uptake rate, but activation of AMPK successfully
further increased fatty acid uptake (91). In addition, insu-
lin did not further increase the elevated sarcolemmal
FIG. 8. Juxtaposition of CD36 and GLUT4 in insulin-resistant muscle. Schematic presentation showing the role of the substrate transporters
CD36 and GLUT4 in myocytes under healthy conditions (top) and a hypothetical model for the development of an impaired GLUT4 translocation
in (pre)diabetic state (bottom). While in healthy conditions, both CD36 and GLUT4 are about equally distributed between endosomes and the
sarcolemma, in the (pre)diabetic state, there is a shift in CD36 localization from the endosomes to the sarcolemma resulting in enhanced fatty acid
uptake, storage of fatty acids into triacylglyceroles (TAG), and subsequent inhibition of insulin signaling by fatty acid metabolites such as
diacylglyceroles and ceramides. Thereafter, translocation of GLUT4 from endosomes to the sarcolemma is inhibited, resulting in lowered glucose
uptake and decreased incorporation into glycogen. At that stage, the muscle has become insulin resistant. FA, (long-chain) fatty acid.
FATTY ACID TRANSPORTERS AND LIPID METABOLISM 399
Physiol Rev • VOL 90 • JANUARY 2010 • www.prv.org
Downloaded from journals.physiology.org/journal/physrev at Universiteit Maastricht (137.120.149.252) on September 27, 2021.
CD36 pool, nor did it further deplete CD36 from the
endosomal stores (91, 322). These observations suggest
that insulin-responsive PI3K/PKB/Akt-mediated endoso-
mal stores are likely the source of the extra amount of
CD36 present at the sarcolemma in the insulin-resistant
heart. This, however, may not be the case in insulin-
resistant skeletal muscle, in which plasmalemmal CD36 is
also permanently upregulated (164), because in this tissue
both insulin and muscle contraction failed to induce a
further increase in plasmalemmal CD36 (164). The fact
that skeletal muscle becomes additionally contraction re-
sistant, in contrast to heart, is a subtle difference between
both tissues in the onset of insulin resistance. This is likely
related to the fact that a safety system is built into the heart
so that it still can increase fatty acid uptake upon increased
contractile performance for the production of energy. None-
theless, in both heart and skeletal muscle, permanent relo-
cation of CD36 from insulin-responsive PI3K/PKB/Akt-medi-
ated endosomal stores is likely a main contributor to the
development of insulin resistance.
What then are the signals that permanently deplete
the insulin-responsive endosomal stores from CD36? A
clue is provided by the elevated basal phosphorylation of
PKB/Akt and its distal target PRAS40 in hearts from high
fat fed rats, whereas AMPK activity was not affected by
the diet. Moreover, increased basal PKB/Akt activity to-
gether with impaired insulin-stimulated PKB/Akt activity
have been reported in skeletal muscle from ob/ob mice
(301). Together these findings suggest that the elevated
basal activity of PKB/Akt may contribute to the sustained
presence of CD36 at the sarcolemma in insulin-resistant
heart and skeletal muscle, although other diet-induced
changes, for instance, in the as yet undisclosed trafficking
machinery regulating CD36 endocytosis and exocytosis
(see sect. VB), might also play a role.
In prediabetic Zucker rats, plasma insulin levels are
sevenfold elevated and might be responsible for CD36
relocalization in heart and muscle (91, 164, 273). In con-
trast, systemic hyperinsulinemia was not observed in high
fat diet fed rats (321). Especially this latter observation
may suggest that changes in the activity of other (insulin-
independent) regulators of PKB/Akt phosphorylation,
such as PI3K	- and 2-adrenergic receptor signaling path-
ways, CaMK, protein phosphatase 2A, and the sympa-
thetic nervous system (126), could perhaps be responsible
for elevated PKB/Akt phosphorylation and subsequent
permanent CD36 relocation to the sarcolemma in the
insulin-resistant heart and skeletal muscle.
D) EMERGING PICTURE OF MECHANISMS INVOLVED. From the
studies in muscles and hearts of high fat fed animals,
obese Zucker rats, and ZDF rats, a picture emerges which
suggests that increased rates of fatty acid transport are
regulated by two mechanisms.
1) With moderate and modest insulin resistance
(high fat feeding and obese Zucker rats), fatty acid trans-
port is increased by the permanent relocation of CD36
from an intracellular depot to the plasma membrane with-
out any alteration in the protein expression of CD36 (273,
322).
2) With more severe insulin resistance (male ZDF
rats, high fat fed female ZDF rats), the total cellular
pool of CD36 is increased (71, 387), which likely allows
for a much greater increase in CD36 at the plasma
membrane.
3. Human studies
There are only a few studies that have examined fatty
acid transport and transporters in human obesity and type
2 diabetes. Understandably, this work is largely descrip-
tive and has necessarily focused on the most accessible
tissues, adipose tissue (not discussed here) and skeletal
muscle.
It was initially reported that skeletal muscle fatty
acid uptake in human muscle is reduced in type 2 diabetes
(35, 476). However, these observations are likely incor-
rect, because these conclusions appear to be based on
problematic, indirect measurements, and the data do not
concur with more recent direct determination of fatty
acid transport rates across the plasma membrane in mus-
cles of diabetic animals (71, 387) or humans with type 2
diabetes (48).
Direct determination of skeletal muscle fatty acid
transport, using giant sarcolemmal vesicles, has shown
that rates of fatty acid transport are markedly increased in
skeletal muscle of obese individuals and those with type
2 diabetes (48). In contrast, just as in some animal models
of insulin resistance (see above), skeletal muscle fatty
acid transporters (FATP1 mRNA and CD36 mRNA and
protein) were not altered in human obesity and type 2
diabetes (34, 48, 330), or were altered inconsistently
(FABPpm protein; Refs. 48, 330, 384). Instead, the increase
in the fatty acid transport rate into obese and type 2
diabetic muscle was associated with an increase in the
plasmalemmal content of CD36 (obesity, 40%; type 2
diabetes, 50–76%; Refs. 18, 48) and FATP4 (type 2 dia-
betes, 20%; Ref. 18), whereas plasmalemmal FABPpm
and FATP1 were not altered (18, 48). Indeed, the increase
in plasmalemmal CD36 in lean, overweight, and obese
individuals and type 2 diabetes patients correlated well
with their increased rates of fatty acid transport (r 
0.93), an index of insulin resistance (48). Moreover, the
rates of fatty acid transport were also positively associ-
ated with the intramuscular triacylglycerol concentra-
tions (r  0.93) (48) (Fig. 9). Notably therefore, in human
obesity and type 2 diabetes, just as in animal models of
insulin resistance (164, 197, 273), skeletal muscle fatty
acid transport into muscle and intramuscular triacylglyc-
erol accumulation are increased largely in association
with the permanent relocation of CD36 to the plasma
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membrane (48), as well as possibly a small increase in the
plasmalemmal FATP4 pool (18).
4. Fiber type-specific and gender differences
A) FIBER TYPE. Skeletal muscles consist of red (oxida-
tive) and white (glycolytic) fibers. Compared with white
muscles, the red muscles have a higher capacity for fatty
acid oxidation and esterification (42, 114, 164) and insu-
lin-stimulated glucose transport (49, 165, 184, 298, 391).
These differences are related, in part, to inherent differ-
ences (red  white muscle) in their expression of PGC-
1, their glucose and fatty acid transport proteins, and
their enzymes for metabolizing fatty acids (23, 45, 184,
298). In view of these differences, the potential dysregu-
lation in these processes may be greater in red muscle.
Indeed, oxidative (red) muscles exhibit a 2.5-fold greater
impairment in insulin-stimulated glucose transport than
glycolytic (white) muscle in response to a high-fat diet
(474), and ZDF rats exhibit a reduction only in red muscle
GLUT4 (	40%) but not in white muscle GLUT4 (128). In
human obesity and type 2 diabetes, excess intramuscular
lipid accumulation (20 to 56%) occurs in red (I and IIa)
but not in white (IIb) muscle fibers (180). There is some
indication that the greater lipid accumulation in red muscles
is related to muscle-specific upregulation of fatty acid trans-
porters and transport in red muscle compared with white
muscle (see below) (Fig. 10). Such fiber-specific differ-
ences could account for the accumulation of red muscle
intramuscular lipids that can interfere with insulin signal-
ing.
An increased fatty acid disposal has been observed in
red but not in white muscles in the high-fat diet-induced
model of insulin resistance, and this was associated with
an increase in red muscle CD36 mRNA (182). Similarly, in
red, but not in white muscle, fasting induced an increase
in plasmalemmal FABPpm (444). In obese Zucker rats,
fatty acid transport (197) and incorporation into triacyl-
glycerol depots (197, 446) are increased more in red mus-
cle than in white muscle. These increased rates of fatty
acid transport into red muscle were twofold greater than
into white obese muscle, and these differences were as-
sociated with a concomitantly greater concentration in
plasmalemmal CD36 in red (increase of 100 arbitrary
units) than in white muscle (increase of 25 arbitrary units)
(197). Other fatty acid transporters located at the plasma
membrane (FABPpm, FATP1 and -4) were not altered in
either red or white muscles of obese rats (164, 197),
except for one report (61% in red muscle plasmalemmal
FABPpm) (446). Along similar lines, in the transition from
insulin resistance to type 2 diabetes in ZDF rats, there was
an increase in red muscle, but not white muscle, fatty acid
transport rates due to concomitant increases in CD36 pro-
tein expression and plasmalemmal content, while no
changes occurred in either red or white muscle plasmale-
mmal FABPpm (71). Moreover, the increase in red muscle
plasmalemmal CD36 was inversely correlated with the plas-
malemmal GLUT4 (r  	0.90) (71).
Taken together, the available evidence indicates that
red muscle exhibits a greater propensity for developing
insulin resistance. This appears to be related, in part, to
changes in intramuscular lipid accumulation in red com-
pared with white muscle, likely as a result of changes in
the expression and/or plasmalemmal content of CD36,





FIG. 9. Triacylglycerol accumulation in human obesity and type 2
diabetes is associated with increased rates of muscle fatty acid transport
and increased plasmalemmal CD36 content. Fatty acid uptake rates and
CD36 were determined in giant sarcolemmal vesicles prepared from
rectus abdominus muscle biopsies obtained from lean [body mass index
(BMI) 25], overweight (BMI  25–30), and obese (BMI 30) individ-
uals and type 2 diabetics. [Redrawn from Bonen et al. (48).]
FIG. 10. Distribution and immunolocalization of CD36 in human
skeletal muscle. A cryosection of human m. vastus lateralis was stained
for CD36, first by incubation with a specific anti-CD36 antibody, which
was followed by incubation with a fluorescently labeled secondary
antibody. Type 1 fibers were identified using antibodies specific for slow
myosin heavy chain (data not shown). CD36 is more abundant in (slow
oxidative) type 1 muscle fibers (indicated by 1) than in (fast glycolytic)
type 2 fibers (2). At the subcellular level, CD36 immunostaining is seen
both at the sarcolemma and in the cytoplasm (punctate staining pat-
tern). [Figure courtesy of Dr. H. A. Keizer (236).]
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B) GENDER DIFFERENCES. It appears that there are gender
differences in insulin resistance and in the responses of
fatty acid transporters to an altered fatty acid milieu and
insulin. Specifically, in male rats, an acute (2 h), fourfold
increase in circulating fatty acids impaired insulin signal-
ing (IRS-1 phosphorylation, 	30%; IRS-1-associated PI3K
activity, 	48%) and induced a 40% reduction in the skel-
etal muscle insulin-stimulated glucose disposal rate. This
was accompanied by a 50% reduction in skeletal muscle
CD36 protein expression (189). Surprisingly, none of
these changes was observed in female rats (189).
Considerable differences in FATP1 mRNA have also
been observed among men and women. FATP1 mRNA
expression in skeletal muscle is 3.7-fold greater in lean
women than in lean men (34), and insulin infusion (3 h)
reduced FATP1 mRNA in lean women but not lean men,
nor in obese nondiabetic and diabetic men and women
(34). In addition, in women, but not in men, BMI and
FATP1 mRNA were inversely related (r  	0.74) (34). In
the absence of any measures of fatty acid transport and in
the FATP proteins in these studies, it is difficult to deter-
mine the pathophysiological significance of these obser-
vations.
Clearly, the few available studies in both animals and
humans do begin to suggest that there may be gender
differences with respect to insulin resistance and fatty
acid metabolism, including fatty acid transport and trans-
porters. This warrants further investigation.
5. Insulin resistance in spontaneously hypertensive
rats is not attributable to CD36 ablation
A series of genetic studies combining the use of
cDNA microarrays, congenic mapping, and radiation hy-
brid mapping in spontaneously hypertensive rats (SHR), a
rat model of insulin resistance and hypertension, sug-
gested that CD36 deficiency is at the peak of linkage to the
SHR alterations in fatty acid and glucose metabolism (7,
89, 337, 338). The authors concluded that CD36 deficiency
provides a plausible basis for the development of insulin
resistance through a primary defect in cellular fatty acid
transport. Support for this notion was provided by the
observation that transgenic rescue of CD36 improved in-
sulin sensitivity (337). We fully agree with the notion that
CD36 is involved in insulin resistance, but we envisage
that an upregulation rather than a downregulation of
CD36 is causal to insulin resistance. In fact, a possible
downregulation of CD36 seems counterintuitive with re-
gard to the accumulation of fatty acids and their metab-
olites in peripheral tissues. Remarkably, in contrast to the
North American SHR strain used in the aforementioned
studies, an SHR strain in Japan did express CD36 (146),
uncoupling CD36 from the development of insulin resis-
tance in this rodent model. The supporting evidence link-
ing an apparent null expression of CD36 in North Ameri-
can SHR with insulin resistance are inconsistent. For
example, transgenic expression of wild-type CD36 in the
North American SHR strain increased glucose disposal
(OGTT) and muscle glycogenesis and reduced circulating
fatty acids (337). Yet, in subsequent work with these CD36
transgenic SHR, neither glucose disposal (OGTT) nor
muscle glucose oxidation was improved (340). In stroke-
prone SHR animals, lipid metabolism differed, despite
similar expression of adipocyte CD36 protein (89). More-
over, other studies suggest that CD36 ablation improves
insulin sensitivity (123, 147), and an increase in CD36 is
linked strongly with insulin resistance (48, 91, 273), as this
leads to an accumulation of intramuscular fatty acid prod-
ucts that can interfere with insulin signaling. From more
recent work it now appears that in fact North American
SHR are not null for CD36 (43). This protein is expressed
in many tissues of these animals albeit at a reduced level
in heart (	26%), red (	40%) and white muscles (	53%),
liver (	75%), and adipose tissue (	46%) (43). Thus it is
very difficult to support the proposition that the North
American SHR strain fails to express CD36 protein and
that a CD36 deficiency underlies insulin resistance in
these animals.
C. Type 1 Diabetes
Lipid metabolism is also altered in type 1 diabetes, an
effect that has been associated with altered fatty acid
transport and transporters. For example, early studies
indicated that heart and skeletal muscle CD36 protein
expression was increased in streptozotocin (STZ)-in-
duced diabetes, an animal model of type 1 diabetes (150,
329), suggesting an important role for this protein in
taking up the increased circulating fatty acids in this
model. Indeed, the intramuscular fatty acids are increased
by 25% in STZ-induced diabetic rats (312). Detailed
studies of moderate and severe STZ-induced diabetes
have revealed tissue-specific responses in fatty acid trans-
port and transporters (272). The relative changes and the
magnitude of changes in fatty acid transport and trans-
porters differed among the tissues examined and/or de-
pended on the severity of diabetes. For example, fatty
acid transport increased progressively with the severity of
diabetes only in the heart (moderate, 71%; severe,
143%). In skeletal muscle, fatty acid transport was up-
regulated to a similar extent in moderate (37%) and
severe diabetes (28%). In contrast, in adipose tissue,
fatty acid transport was not changed with moderate dia-
betes but upregulated (171%) in severe diabetes (272).
Concurrent with these changes in fatty acid transport,
there were also concomitant changes in the protein ex-
pression and plasmalemmal content of CD36 (muscle and
heart) and FABPpm (severely diabetic heart only), while in
adipose tissue the CD36 plasmalemmal content, but not
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its protein expression, was increased in severe diabetes.
These changes in protein expression were not consis-
tently related to changes in the mRNAs of these transport-
ers. However, it could be shown that the changes in the
rate of fatty acid transport in these different tissues was
related to the presence of both CD36 and FABPpm at the
plasma membrane (272). Collectively, these studies indi-
cate that changes in CD36 and FABPpm occur in animal
models of type 1 diabetes, but the extent to which these
changes contribute to altered fatty acid metabolism in the
STZ-induced diabetic animal model remains to be deter-
mined.
VIII. CONCLUSIONS AND PERSPECTIVES
Membrane fatty acid transporters have emerged as a
group of proteins serving a pivotal role in whole body lipid
metabolism. By facilitating the transmembrane transport of
fatty acids, these proteins dramatically accelerate fatty acid
transport into cells (and their release from adipocytes). In
addition, cellular entry of fatty acids appears to be regulated
acutely by changes in plasmalemmal fatty acid transporter
content, which occurs in response to selected stimuli (e.g.,
muscle contraction, insulin) and involves the translocation
of specific fatty acid transporters from an intracellular stor-
age compartment to the plasmalemma. Fatty acid transport-
ers thus form an integral part of a complex network of
plasma and cellular proteins that enable a rapid availability
and unrestricted use of fatty acids in the cell yet keep them
from exerting potential harmful effects related to their am-
phiphilic (“soaplike”) characteristics. Finally, the occur-
rence of various types of fatty acid transporters with each
displaying a characteristic pattern of tissue distribution fur-
ther illustrates their role in cellular lipid homeostasis tuned
to the metabolic requirements of a specific tissue. While the
focus of this review was on heart and skeletal muscle, the
concepts outlined for these tissues generally will presum-
ably apply to all tissues with an active fatty acid metabolism.
A. Integration of Regulatory Steps
The new insights on the functioning of fatty acid
transporters have further underscored the striking simi-
larity between the regulation of the cellular utilization of
fatty acids and that of glucose. This similarity relates to
1) the occurrence of a relatively small number of distinct
proteins facilitating transmembrane substrate transport,
2) a tissue-specific expression pattern of these proteins,
and 3) acute translocation of selected proteins to the
plasma membrane in response to physiological stimuli,
notably muscle contraction and insulin, to regulate cellu-
lar substrate uptake. It appears that nature has generated
quite similar systems to safeguard a properly regulated
cellular entry of two main substrates, long-chain fatty
acids and glucose. A major corollary of these findings is
that cellular fatty acid utilization, just like that of glucose,
is regulated at three levels, i.e., 1) substrate delivery,
2) cellular uptake, and 3) intracellular metabolism (oxi-
dation, storage, and so on, including substrate competi-
tion at the level of mitochondria).
Fatty acid transporters, just like GLUTs, function as
a link among various metabolic regulatory steps aimed at
adjusting cellular substrate metabolism and referred to as
“metabolic coordination.” For instance, muscle contrac-
tion, through activation of AMP kinase, increases the
translocation of fatty acid transporters (CD36) to the
sarcolemma to increase fatty acid uptake, and concomi-
tantly increases mitochondrial fatty acid oxidation to pro-
duce ATP needed to sustain contraction. As a result,
proper functioning of fatty acid transporters is of central
importance to maintain homeostasis, and derangements
therein likely will result in pathology (see below).
1. Functioning of fatty acid transporters
The molecular mechanism explaining the functioning
of fatty acid transporters is not yet clear. Specifically, it is
not known 1) whether fatty acid transporters function alone
or as a (heteromeric) complex (e.g., CD36 and FABPpm),
2) whether they act as transmembrane transporters or
3) merely function as docking site or cell surface receptor
for fatty acids, whereafter the fatty acids cross the plasma
membrane by simple diffusion, 4) whether the functioning
of fatty acid transporters is dependent on or influenced by
accessory proteins or by the lipid microenvironment, and
finally 5) whether posttranslational modifications (palmi-
toylation, phosphorylation) would further influence their
functioning. Importantly, the mode of action of fatty acid
transporters may also differ among the key tissues involved
in fatty acid handling. In this respect, it has been shown that
the protein expression of each of the fatty acid transporters
(FABPpm, CD36, FATP4, but not FATP1) is graded among
muscle tissues in relation to their well-known differences in
fatty acid utilization, i.e., heart  red muscle  white
muscle (45, 197, 286, 314, 329, 459). However, absolute quan-
tities have been assessed only for CD36 (329) so that a
quantitative comparison among fatty acid transporters is not
yet possible.
Further insight into the molecular functioning of
fatty acid transporters could also be obtained from their
three-dimensional protein structures. However, unfortu-
nately, a detailed structure is not yet known for any of the
fatty acid transporters (cf. Fig. 1, B and C). Although
computer predictions of the protein structure based on
the primary amino acid sequence have been presented for
CD36 (156) and FATP (107), and some protein character-
istics are known for FABPpm (419), these models must be
interpreted with great caution as they may not represent
the real structure.
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It has been argued that each of the fatty acid trans-
porters also is known to support other metabolic func-
tions, e.g., mitochondrial AspAT (FABPpm), multifunc-
tional ligand receptor (CD36), and (very-long-chain) acyl-
CoA synthetase (FATPs) (see sect. III). These findings
have been interpreted to suggest that their functioning in
cellular fatty acid uptake is artifactual. However, it should
be noted that assigning dual functions to specific proteins
is not uncommon. For instance, -catenin functions in
both cellular adhesion and transcriptional regulation (53),
and integrins function both in cell adhesion and in cellular
signaling (303).
2. Is protein-mediated fatty acid transport
rate-limiting in fatty acid utilization?
In heart and muscle, glucose uptake mediated by
the glucose transporter GLUT4, except during exercise
(130), is considered the rate-limiting step in cellular
glucose utilization (for review, see Refs. 207, 365, 428).
Similarly, but perhaps not during exercise (242), it is
also possible that protein-mediated fatty acid transport
across the sarcolemma is rate-limiting in cardiac and
muscular fatty acid utilization. Several lines of evi-
dence do support this view.
First, the intracellular fatty acid concentration re-
mains low at saturating fatty acid concentrations (see
sect. IIB). This observation does not only indicate that the
saturation kinetics of cellular fatty acid uptake reflects
saturation of sarcolemmal transport rather than satura-
tion of metabolism (287), but also supports the notion
that fatty acid uptake may be a rate-limiting step in car-
diac and muscular fatty acid utilization (285). Second, the
fatty acid uptake kinetics in the presence (cardiac myo-
cytes) and absence of metabolism (giant sarcolemmal
vesicles) display a similar apparent Km for fatty acid
uptake (285, 286). Third, a recent study (283) showed that
CPT-I, which converts fatty acyl-CoA into fatty acyl-L-
carnitine and is generally thought to be the rate-limiting
step in cardiac fatty acid utilization (for review, see Ref.
296), cannot be the only parameter governing the rate of
fatty acid utilization. Specifically, a chronic partial
(50%) inhibition of CPT-I by administration of etomoxir
to rats did not affect fatty acid uptake and metabolism by
cardiac myocytes (283), strongly arguing against CPT-I as
the primary site determining cardiac fatty acid fluxes. As
a result, other sites in cardiac fatty acid utilization, most
notably sarcolemmal protein-mediated fatty acid trans-
port, may also function in regulating cardiac fatty acid
flux. The mechanism of such regulation may differ among
the various fatty acid transporters but will include intra-
cellular translocation of fatty acid transporters to the
plasma membrane (see sect. IVA) and to mitochondria
(see sect. IVC), and may also comprise modulation of their
involvement by, for instance, changes in the interaction
with accessory proteins.
B. Fatty Acid Transporters as Potential
Therapeutic Targets
The role of fatty acid transporters in the control of
cellular fatty acid uptake under normal conditions and
their implication in metabolic alterations occurring in
certain disease conditions suggest that fatty acid trans-
porters are an attractive therapeutic target to manipulate
cellular fatty acid utilization. This would apply especially
to obesity and insulin resistance whereby increased rates
of fatty acid transport are a key factor contributing to the
intracellular lipid accumulation in heart and muscle tis-
sue, which in turn interferes with the insulin signal trans-
duction cascade required to induce GLUT4 translocation
(see sect. VIIB). Indeed, in studies in which CD36 has been
ablated (147) or in which the increase in plasmalemmal
CD36 content has been prevented (387), there is clear
evidence of an improved insulin sensitivity (i.e., blunting
the progression of high-fat diet-induced insulin resis-
tance). In addition, CD36 ablation was found to rescue
myocardial lipotoxicity and myocardial dysfunction in-
duced by PPAR overexpression (480). To date, there are
as yet no effective pharmacological agents that specifi-
cally inhibit fatty acid transport. Unfortunately, the CD36
inhibitor SSO is unsuitable for use in vivo due to its
limited stability in solution. Nevertheless, development of
inhibitors that limit fatty acid uptake would represent a
novel therapeutic strategy against insulin resistance.
In a broader perspective, manipulation of cellular
substrate uptake by modulating the presence or function-
ing of specific substrate transporters in the plasma mem-
brane has been suggested as a means to alter cellular
substrate preference (140). Such an approach is expected
to be of interest not only for heart (140) but also for
skeletal muscle, as intermediary metabolism is regulated
similarly in these organs while both are sensitive to a
chronic change in the balance of glucose and fatty acid
utilization. Theoretically, modulating the cellular distribu-
tion of, in particular, the substrate transporters GLUT4
and CD36 in the diseased heart or muscle may normalize
substrate metabolism and allow them to function nor-
mally. In practice this would require the selective recruit-
ment of either GLUT4 or CD36 to the membrane, or their
selective internalization, while so far it was found that
these transporters respond to physiological stimuli (con-
traction, insulin) by their simultaneous recruitment (see
sect. IVA). However, proof of concept for such selectivity
comes from studies in rat cardiomyocytes indicating that
arsenite (282) and dipyridamole (274) specifically recruit
GLUT4 and CD36, respectively, leading to selectively in-
creased glucose and fatty acid utilization, respectively.
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Although the intracellular targets of these pharmacologi-
cal compounds are not known, most likely they activate
or inhibit trafficking proteins specifically involved in ei-
ther GLUT4 or CD36 translocation (376). As a result, these
recent findings illustrate the feasibility of the general
concept that selective transporter translocation can be
applied to alter substrate preference and thus holds prom-
ise as a target for so-called metabolic modulation therapy
(422).
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